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1.  SUMMARY  	  
Motivation and Aim: 
Cardiovascular disease has been the leading cause of mortality and morbidity throughout the 
world. In developed countries, cardiovascular diseases are already responsible for a majority 
of deaths and will become the pre-eminent health problem worldwide (1,2). Rupture of 
atherosclerotic plaque accounts for approximately 70% of fatal acute myocardial infarction and 
sudden heart deaths. Conventional criterias for the diagnosis of “vulnerable plaques” are 
calcified nodules, yellow appearance of plaque, a thin cap, a large lipid core, severe luminal 
stenosis, intraplaque hemorrhage, inflammation, thrombogenicity, and plaque injury (3-5). 
Noninvasive diagnosis of vulnerable plaque still remains a great challenge and a huge 
research prospect, which triggered us to investigate the feasibility of PET imaging on the 
evaluation of atherosclerosis. Nuclear imaging of atherosclerosis， especially co-registered 
imaging modalities, could provide a promising diagnostic tool including both anatomy and 
activities to identify vulnerable atherosclerotic plaque or early detection of inflammatory 
endothelium at risk. Furthermore, the development of specific imaging tracers for clinical 
applications is also a challenging task. The aim of this work was to assess the potential of 
novel PET imaging probes associated with intra-plaque inflammation on animal models and in 
human respectively. 
Methods 
In this work, several molecular imaging modalities were employed for evaluation of 
atherosclerosis. They included Positron emission tomography / Computed tomography 
(PET/CT) for human studies, and micro-PET, autoradiography and high-resolution magnetic 
resonance imaging (MRI) for animal studies. Radiotracers for PET imaging included the 
glucose analogue 18F-Fluorodeoxyglucose (18F-FDG), the somatostatin receptor avide tracer 
68Ga-DOTATATE, and the Gallium-68 labeled fucoidan (68Ga-Fucoidan), which was developed 
as a PET tracer to detect endothelial P-selectin, which overexpressed at early stage of 
atherosclerosis and endothelial overlying activated plaque. Tracer’s capabilities were firstly 
assessed on cellular level in vitro. Subsequently, Animal studies were conducted in two animal 
models: 1, Apolipoprotein E (ApoE-/-) mice having severe atherosclerotic plaque; 2, 
Lipopolysaccharide (LPS) -induced mice for receiving acute vascular inflammation. 
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Corresponding analyses on protein and histological level were conducted as well to confirm 
our results. 
In human study, 16 patients with neuroendocrine tumors (NETs) were investigated on imaging 
vascular inflammation. These patients had undergone both 68Ga-DOTATATE PET/CT and 18F-
FDG PET/CT for staging or restaging within 6 weeks. 16 patients were randomized into two 
groups: high-risk group and low-risk group. Uptake ratio of both tracers from two groups were 
compared and correlated with common cardiovascular risk factors. 
Results and Conclusion 
In murine study, the expression of somatostatin receptor 2, which is the main bio-target of 
68Ga-DOTATATE on macrophage/monocyte was confirmed by flow cytometry and 
immunohistochemistry. Prospectively, high specific accumulation of 68Ga-DOTATATE to the 
macrophage within the plaques was observed in aorta lesions by autoradiography and by 
micro-PET. In study with 68Ga-fucoidan, a strong expression of P-selectin on active 
endothelium overlying on inflamed plaque but weaker on inactive plaques was confirmed. 
Specific focal uptake of 68Ga-fucoidan were detected at aorta segments by micro-PET, and 
correlated with high-resolution magnetic resonance imaging (MRI), which was used to 
characterize the morphology of plaques. 68Ga-fucoidan also showed a greater affinity to active 
inflamed plaque in comparison of inactive fibrous plaque, which was assessed by 
autoradiography.  Specificity of 68Ga-DOTATATE and 68Ga-fucoidan were confirmed by ex-vivo 
blocking autoradiography and in vivo blocking PET imaging respectively. 
In human study, focal uptake of both 18F-FDG and  68Ga-DOTATATE was detected. Analyzing 
concordance of two tracers’ uptake ratio, Out of the 37 sites with highest focal 68Ga-
DOTATATE uptake, 16 (43.2%) also had focal 18F-FDG uptake. Of 39 sites with highest 18F-
FDG uptake, only 11 (28.2%) had a colocalized 68Ga-DOTATATE accumulation. Correlated 
tracers’ uptake and calcium burden and risk factors, Mean target-to-background ratio (TBR) of 
68Ga-DOTATATE correlated significantly with the presence of calcified plaques (r=0.52), 
hypertension (r=0.60), age (r=0.56) and uptake of 18F-FDG (r=0.64). TBRmean of 18F-FDG 
correlated significantly only with hypertension (r=0.58; p<0.05). Additionally, TBRmean of 
68Ga-DOTATATE is significant higher in the high risk group while TBRmean of 18F-FDG is not. 
In conclusion, we evaluated vascular inflammation of atherosclerosis non-invasively using the 
two PET tracers: 68Ga-DOTATATE and 68Ga-Fucoidan. 68Ga-DOTATATE show specific affinity 
to infiltrated macrophage within the plaques. 68Ga-Fucoidan may hold the potential to 
discriminate between active and inactive atherosclerotic plaques in terms of variant 
accumulation on different-types of plaques.  PET as leading molecular imaging technique 
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provides superiority in assessing cellular activity, which is pivotal for understanding internal 
activity of atherosclerotic plaques. Since diagnosis of atherosclerosis is a complex and multi-
dimensional task.  More integrated imaging technology such as PET/MRI, faster imaging 
algorithm, more efficient radiotracer are required for further development of atherosclerosis 
imaging, 
 
Zusammenfassung	  	  
	   4	  
ZUSAMMENFASSUNG  
Ziel: 
Kardiovaskuläre Erkrankungen stellen die häufigste Todesursache der westlichen 
Industrieländer dar und führen zu einem zunehmenden Gesundheitsproblem weltweit. (1,2). 
Ca. 70 % aller akuten Myocardinfarkte sind auf die Ruptur atherosklerotischer Plaques zurück 
zuführen, deren typische Charakteristika ein kalzifizierter, lipidhaltiger Kern, überzogen von 
einer dünnen fibrösen Kappe, darstellt. Innerhalb der atherosklerotischer Plaques kommt es 
zu Makrophageneinlagerung und im weiteren Verlauf zu entzündlichen und angiogentischen 
Prozesse, die zu Einblutungen führen und die Instabilität der Plaques zur Folge hat (3-5). Die 
nichtinvasive Diagnostik rupturgefährdeter Plaques stellt immer noch eine große medizinische 
Herausforderung dar. Die nuklearmedizinische Bildgebung, kombiniert mit MRT/CT zur 
anatomischen Co-Registrierung, könnte eine verbesserte diagnostische Methode zur 
Darstellung rupturgefährdeter atherosklerotischen Plaques und frühzeitiger entzündlicher 
Prozesse darstellen. Ziel dieser Arbeit war es daher, atherosklerosische Plaques mittels 
Positronenemissionstomografie (PET) unter Verwendung neuer PET Tracer für die Darstellung 
von Entzündungsprozesse im Tiermodell und der humanen Anwendung zu untersuchen. 
Material und Methoden: 
Im Rahmen dieser Arbeit kamen verschiedene bildgebende Verfahren zur Anwendung. Im 
Einzelnen waren dies PET/CT bei humanen Studien sowie micro-PET, Autoradiografie und 
hochauflösende Magnetresonanztomografie (MRT) bei Untersuchungen im Tiermodell. Als 
PET-Tracer wurden das Glukosederivat 18F-Flurodesoxyglukose (18F-FDG),  68Ga-DOTATATE, 
das an Somatostatin-Rezeptoren bindet sowie Gallium-68 markiertes Fucoidan (68Ga-
Fucoidan) verwendet. Bei 68Ga-Fucoidan handelt es sich um einen neu entwickelten PET-
Tracer zur Darstellung von P-Selectin, welches an aktivieren Plaques im frühen Stadium der 
Atherosklerose überexprimiert wird. Die Untersuchungen im Tiermodell fanden sowohl an 
Apolipoprotein E Knockout-Mäusen  (ApoE-/-) als auch an Lipopolysaccharid- (LPS) 
induzierten Mäusen statt. Des Weiteren wurden uptake-Untersuchungen auf in 
Zellkulturexperimenten durchgeführt. Zur Bestätigung der der Untersuchungsergebnisse 
wurden zusätzlich histochemische Untersuchungen durchgeführt. Im Rahmen der humanen 
Studien wurden 16 Patienten mit neuroendokrinenen Tumoren (NET) hinsichtlich vaskulärer 
Entzündungsprozesse untersucht. Alle Patienten erhielten ein 68Ga-DOTATATE PET/CT und 
18F-FDG PET/CT zum Staging bzw. Restaging innerhalb von 6 Wochen. Die Einteilung der 
Patienten erfolgte in zwei Gruppen: hohes Risiko und geringes Risiko. Die uptake-Verhältnisse 
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beider Tracer in beiden Gruppen wurden mit einander verglichen und hinsichtlich bekannter 
cardiocaskulärer Risikofaktoren in Beziehung gesetzt. 
Ergebnisse und Zusammenfassung: 
Die Expression der Somatostatin-Rezeptor Subtyps 2, an den 68Ga-DOTATATE an 
Makrophagen/Monocyten bindet, konnte mittels flow cytometrischer und 
immunhistochemischer Experimente im Mausmodell bestätigt werden. Mit Hilfe von micro-PET 
Untersuchungen und Autoradiografie wurde eine hohe spezifische Anreicherung von 68Ga-
DOTATATE an Makrophagen innerhalb der Plaques beobachtet.Im Rahmen der 
Untersuchungen mit 68Ga-Fucoidan konnte eine hohe P-Selectin-Expression an aktiviertem 
Endothelium, welches die entzündlichen Plaques überlagert festgestellt werden. Bei inaktiven 
Plaques hingegen zeigte sich eine geringe P-Selectin-Expression. In micro-PET-Studien 
konnte ein spezifischer fokaler uptake von 68Ga-Fucoidan in der Aorta nachgewiesen werden. 
Dieser korrelierte mit den zusätzlich durchgeführten MRT-Untersuchungen zur 
Charakterisierung der Plaquemorphologie. Mittels Autoradiografie konnte nachgewiesen 
werden, dass 68Ga-Fucoidan eine höhere Affinität zu aktivierten entzündlichen Plaques im 
Vergleich zu inaktivieren fibrösen Plaques zeigt. Die spezifische Bindung  von 68Ga-
DOTATATE und 68Ga-Fucoidan wurde über Blockadeexperimente mittels Autoradiografie und 
PET bestätigt. In der humanen Anwendung wurde ein fokaler uptake von 18F-FDG und 68Ga-
DOTATATE detektiert. Die Analyse der Übereinstimmung des uptakes beider Tracer ergab: 
Von 37 spots mit hohem 68Ga-DOTATATE-uptake zeigten 16 (43,2 %) ebenfalls einen fokalen 
18F-FDG -uptake. Von 39 spots mit hohem 18F-FDG -uptake zeigten nur 11(28,2%) eine 68Ga-
DOTATATE-Anreicherung. Betrachtet man den Tracer-uptake hinsichtlich des Calcium-burden  
und weiterer Risikofakoren, so ergeben sich folgende Korrelationskoeffizienten: TBRmean of 
68Ga-DOTATATE korreliert signifikant mit der Anwesenheit von kalzifizierten Plaques (r=0,52), 
Blutdruck (r=0,60), Alter (r=0,56) und 18F-FDG uptake (r=0,64). Eine signifikante Korrelation 
von TBRmean 18F-FDG konnte lediglich beim Risikofaktor Blutdruck (r=0,58, p<0,05) 
festgestellt werden. Weiterhin zeigte sich, dass der TBRmean von Ga-DOTATATE in der Hoch-
Risiko-Gruppe signifikant höher, dies gilt jedoch nicht für TBRmean 18F-FDG. 
Zusammenfassung: 
In dieser Arbeit wurden die vaskulären Entzündungsprozessen der Atherosklerose mittels der 
nichtinvasiven PET unter Verwendung von 68Ga-DOTATATE und 68Ga-Fucoidan untersucht 
und bewertet. 68Ga-DOTATATE zeigte eine spezifische Affinität zu Makrophagen innerhalb der 
atherosklerotischen Plaques. Mit 68Ga-Fucoidan konnt zwischen aktiven und inaktiven Plaques 
unterschieden werden.  
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Die molekulare Bildgebung mittels PET eignet sich hervorragend zur Darstellung und 
Untersuchung molekularer Prozesse innerhalb atheroskerotischer Plaques. Dennoch sind 
weiterführende Technologien wie PET/MR, schnellere Algorithmen, hoch spezifische 
Radiotracer zur Weiterentwicklung der PET-Bildgebung atherosklerotischer Plaques 
notwendig.     
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2.  INTRODUCTION 
Atherosclerosis is a continuously progressive disease. Atherosclerotic lesions are asymmetric 
thickenings of the inner layer of artery, the intima proliferation. Inflammatory cells constitute a 
pivotal part of atherosclerosis. The atherosclerotic lesions (plaques) principally occur in large 
and medium-sized arteries and are able to cause ischemia of the heart or brain (6-9).  
 
2.1  Inflammatory features of atherosclerosis   
Inflammation is increasingly recognized as the major pathogenic link between clinical 
cardiovascular risk factors and acute plaque events. Leukocyte subsets accumulate in 
atherosclerotic lesions at various stages and participate pathological alternation during 
formation of atherosclerosis.  
 
2.1.1 Activation of early endothelial inflammatory processes 
A large number of pathophysiologic founding on formation atherosclerosis suggested that 
endothelial dysfunction was the first step in atherosclerosis (10,11). 
After activation of vascular endothelium, an increased plasma concentration of inflammatory 
mediators is characteristic of inflammatory processes during the formation of atherosclerosis. 
The activation can lead to up-regulation of adhesion molecules, such as intracellular adhesion 
molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), integrins, and selectins (L, 
E, and P) will lead to the rolling and adhesion of immune cells (monocytes, macrophages, 
platelets, and T lymphocytes) onto the endothelial wall. This activation of the endothelium 
leads to the release of pro-inflammatory cytokines, surface receptors, and proteinase enzymes 
including Tumor necrosis factors (TNF-α), interleukins, interferons, monocyte chemoattractant 
protein-1 (MCP-1) (3,12-14)  (Fig.1). 
 
2.1.2 Mechanisms of leukocyte 
Previous studies have established that, once adherent to the endothelium, leukocytes 
subsequently enter the intima by diapedesis between endothelium at their gaps. This 
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phenomenon of directed migration of leukocytes through the endothelium has yielded to 
molecular analysis. Investigators have defined families of chemoattractant cytokines 
(chemokines) capable of recruiting leukocytes into the arterial intima. Such as  MCP-1, which 
overexpressed in atheroma (15) (Fig.1 ). 
 
Figure 1: The endothelial dysfunction cascade after inflammatory activation at early atherosclerosis. 
Interactions between leukocytes and endothelium. Leukocyte - endothelial cell contacts are initiated by 
selectin-dependent tethering and rolling, followed by chemokine-mediated activation, firm adhesion and 
spreading by integrin, finally, extravasation into the subendothelial space. 
 
Once resident in the arterial intima, monocytes differentiate to the macrophages 
morphologically, undergoing a series of changes subsequently lead to foam cell. The 
monocytes stimulated expression of scavenger receptors from modified lipoproteins such as 
the scavenger receptor A (SRA) and CD36, and internalize modified lipoproteins (16-19). 
These lipid-laden macrophages are known as foam cells, they characterize the early 
atherosclerotic lesion, so called “fatty streak”, which present commonly in infants (20,21).  
 
2.1.3 Inflammation in atherosclerosis progression and complication 
After formation of fatty streak, the initial atheroma normally evolves into a more advanced 
lesion, which can eventually cause severe clinical manifestations. During the progression, fatty 
streaks evolve into advanced atheroma through proliferation of smooth muscle cells, which 
accumulate in the atherosclerotic plaques and secrete extracellular matrix (22,23). Growth 
factors laid out by macrophages in the atherosclerotic plaque stimulated the smooth muscle 
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replication, involved in lesion growth. Following progressing of more complicated atheroma, 
the arterial lumen is continued narrowing until it hinders blood flow and cause clinical 
manifestations.   
  
2.1.4 Inflammation associates plaque disruption 
Current evidence demonstrates that disruption of plaques trigger thrombosis, which can cause 
expansion of atheroma. And inflammation is able to trigger various forms of plaque disruption. 
The main type of physical disruption and most common mechanism of plaque disruptions is 
the fracture of plaques’ fibrous cap. The inflammation contributes to the fracture of plaques’ 
fibrous cap. Since invasive coagulation factors in main pro-thrombotic stimulator, the function 
of fibrous cap is to insulate lipid-rich core of the plaque from bloodstream containing 
coagulation proteins. And gap from ruptured fibrous cap allows the coagulation proteins 
contact with lipid core, which lead to plaque disruption.  
Additionally, there are two other forms of plaques disruption, superficial erosion of 
atherosclerotic plaques and disruption of the micro-vessels.  
In superficial erosion of plaques, main two processes related to inflammation could cause 
endothelial desquamation. Firstly inflammatory mediators production or vascular injury from 
cytolysis by activated killer T cells lead to endothelial cell apoptosis. Moreover, oxidized 
lipoproteins are able to induce the expression of matrix metalloproteinases (MMPs), whose 
function is in degrading endothelial membrane. Therefore, activation of inflammation is able to 
induce the endothelial enzymes that degrade the extracellular matrix element leading 
promoted degradation of endothelium.  
The inflammation is also related to formation of microvessel disruption. The plaque 
microvasculature contributes plaque lesion by two ways, promoting plaque growth and internal 
haemorrphage. The microvessel proceeding is similar to the formation of common 
angiogenesis. Apart from secreting growth factors for smooth muscle cells, inflammatory cells 
within the plaque, also produce antigenic mediators such as fibroblast growth factor and 
vascular endothelial growth factor (VEGF), which enhance atherosclerotic plaque progression 
(24-30).  
Overall, as the understanding of the pathophysiology of lesion-instability is continuous 
developing, a coincident and normalized evaluation method regarding vulnerability is 
necessary. In histopathology, atherosclerosis is characterized by a progressive accumulation 
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of lipids, cells (smooth-muscle cells, macrophages, and T-lymphocytes) and extracellular 
matrix in the arterial wall (31). In the molecular level assessments, foam cells (lipid-laden 
macrophages) are seem to be the central role in the vicious circle of the atherosclerosis 
development; however, many other cells are involved in this process as well. Cell recruitment 
from the blood is followed by migration of cells such as T cells and massive other immune 
cells. On the vessel wall, smooth muscle cells are activated to a proliferative and secretory 
phenotype. A physiological cascade of signaling pathways such as endothelial activation, 
proliferation, angiogenesis, enzymatic reactions, and apoptosis causes evolution to the 
formation of an advanced atherosclerotic plaque.  
 
2.2 Oxidative stress in plaque formation  
Atherosclerosis is a continuously progressive disease visualized by the accumulation of 
cholesterol laden macrophages. It leads to a proliferation of endothelial and smooth muscle 
cells within the arterial wall. These early lesions in atherosclerosis called “fatty streak” 
(21,32,33). Fatty streaks are not clinically significant, but they are the precursors of more 
severe lesions advanced by the accumulation of lipid-rich necrotic debris (34). They are 
associated with an increased production of free species named reactive oxygen species 
(ROS) (35). Oxidative stress reflects increased production of ROS. Previous studies 
demonstrated that oxidative stress plays a pivotal role in the pathogenesis of atherosclerosis, 
especially vascular endothelial dysfunction (36,37); especially ROS is able to injure cell 
membranes, ROS trigger the formation of oxidized low-density lipoproteins (LDL), the main 
component of atherosclerotic plaque (38). The endothelium becomes more permeable to 
leucocytes and lipid molecules, subsequently leading increased macrophages uptaking 
oxidized LDL, then becoming foam cells. Foam cells in turn lead to an enhancement in 
inflammatory cytokine production (Fig. 2)  
Introduction	  
	   11	  
 
Figure 2: Oxidative stress in atherosclerosis. An increase of free radical production is associated with 
atherosclerosis progressing. It provoke an oxidative modification from low-density lipoprotein (LDL) to 
oxidized LDL. Circulating monocytes migrate to the injury site at attach to endothelium by adhesion 
molecules, and subsequently infiltrate into subendothelial space, which is stimulated by ox-LDL and 
under effect of Monocyte chemo attractant protein-1 (MCP-1). The ox-LDL can is taken up by 
macrophages, which become foam cells, leading to the formation of atherosclerotic plaque. 
 
Overall, oxidative modifications on the arterial wall promote the development of 
atherosclerosis. Advanced atherosclerosis embodies itself morphologically as known as 
atherosclerotic plaques. Plaques contain a central lipid core developed from ox-LDL like 
macrophage, that is most often hypocellular and may even include cholesterol that have 
formed in the aftermath of necrotic foam cells. Macrophages accumulate and transform into 
necrotic cores characteristic of advanced, complicated lesions. Although Extension of plaque 
lesions can block blood flow, the most crucial clinical complication is an acute occlusion due to 
the formation of a thrombus, causing myocardial infarction if happen at coronary arteries, or 
stroke if happen at carotid arteries.  
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2.3 Molecular imaging in cardiovascular research 
Molecular imaging (MI) is widely defined as the molecular characterization of biological 
processes in vivo. MI methods can visualize, characterize, and measure the biological 
progresses at molecular and cellular levels (39-41). It differs from conventional functional 
diagnostic imaging, which is used to examine the dysfunctional alternation on anatomic level 
rather than the cellular abnormalities that are more pivotal for disease assessment (42). 
Development of specific, sensitive and high-resolution molecular imaging technologies 
requires connection with basic medical or biological research, which can reveal new unique 
ligands, and imaging techniques by exploiting new imaging programming. These two aspects 
have a common interest in developing of state-of-the-art molecular imaging techniques. 
Several attempts have been undertaken to develop or to improve applications of MI in 
cardiovascular research. However, Sensitivity to imaging molecular alternations require 
optimize compensation for signal loss in dynamic motion, and improved co-registration of 
molecular and anatomical imaging is also required (43-45). Imaging of specific biomarkers will 
lead to early detection and characterization of disease, more accurate assessment of therapy 
response, and a better understanding of the disease process. Therefore, more and more 
significant advances in molecular imaging were noticed. The common molecular imaging 
modalities are listed (Table 1). They include magnetic resonance imaging (MRI), positron 
emission tomography (PET), single photon emission computed tomography (SPECT), optical 
imaging and ultrasound. Each technique has its own unique applications, advantages, and 
limitations. Vascular biology of atherosclerosis suggests several molecular processes that 
could serve as imaging targets (Table 2).  
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Table 1. Common Molecular Imaging Modalities 
Imaging 
Modality 
Spatial 
resolution 
[mm] 
Sensitivity 
(mol/L) 
Probe 
Advantages Disadvantages 
Optical 
Imaging 
<1(FRI);1(FM
T) 
Likely 10-9 
_- 10-12 
High sensitivity, numerous 
selections of probes in 
preclinical study 
Low depth, attenuation 
of signal, Limited 
clinical potential 
PET 1-2 (µ-PET) 
6-10 (clinical 
PET) 
10-11_10-12 High sensitivity, clinical 
translation, functional 
quantitative. Higher spatial 
resolution than SPECT 
Radioactive, Relatively 
low spatial resolution 
SPECT 0.5-2 (µ- 
SPECT); 7-15 
(clinical 
SPECT) 
10-10_10-11 High sensitivity, clinical 
translation, functional 
quantitative 
Radioactive, Relatively 
low spatial resolution 
MRI 0.01-0.1 (high 
resolution 
MRI); 0.5-1.5 
(clinical MRI) 
10-3_10-5 High spatial resolution, 
Superb soft-tissue 
discrimination; anatomic and 
functional data 
Low sensitivity, long 
scan and imaging 
processing time, 
limited probes 
quantitative 
Ultrasound 0.04-0.1 (high 
frequency 
US);0.15-1 
(clinical US) 
Single 
micro-
bubble 
Real-time, superb blood 
imaging, low-cost, easy 
operation, portable 
Low targeting contrast 
agent efficiency, low 
specificity 
 
FRI: fluorescence reflectance imaging; FMT: fluorescence molecular tomography, PET: positron 
emission tomography; SPECT: single photon emission computed tomography; MRI: magnetic 
resonance imaging; 
 
 
Table 2. Molecular targets in atherosclerosis 
Targets Examples 
Endothelial activation(46) 
Adhesion molecules, class II histocompatibility 
molecules (47,48) 
Accumulation and 
activation of cells 
White blood cells (especially monocytes), smooth 
muscle cells 
Visualization of inflammatory 
mediators Fractalkine, chemokine receptors (49-52) 
Metabolic activity of cells within 
atherosclerotic plaque Glucose transport (53-55) 
Plaque procoagulant activity Tissue factor, factor XIII (56) 
Proteolytic enzymes 
Cathepsin K, matrix-metalloproteinases (57-59): 
gelatinases and collagenases 
Reactive oxygen species Superoxide anion (O2-) (60), hypochlorous acid 
Angiogenesis markers Integrin aVb3 (61) 
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2.3.1 Magnetic resonance imaging  
Magnetic resonance imaging (MRI) is a well-established imaging method for different kinds of 
chronic and acute inflammation in numerous diseases. The current development in spatial 
resolution and constructive contrast agent make it a promising imaging technique for the 
characterization of inflammatory vessel walls and atherosclerotic plaque. 
In the last twenty years, MRI was continuously developing by enhancing spatial resolution and 
reducing imaging acquisition time, thereby providing more detailed physiopathological 
information for diagnosis. The most outstanding advantage of MR imaging is its flexibility 
combining different sequences and modified contrast agents. For atherosclerosis investigation, 
novel advances in coil design binding with faster imaging acquisition technologies increased 
spatial resolution, enabling unstable atherosclerotic plaque to be non-invasive visualized with 
a high signal-to-noise ratio in patients.  
Additionally, MRI is performed to detect atherosclerotic plaques by using multi-contrast 
acquisition methods with or without contrast agent administration. However, for the evaluation 
of unstable plaques among stable plaques, more specific, sensitive contrast agents required to 
be designed. The major drawback remains the selecting of biological target, multi-functional 
design of contrast agents to achieve this goal.  
2.3.2 Optical imaging 
Optical imaging (OI) is widely used preclinically based on the detection of light photons after 
their interaction with the disease lesions. Bioluminescence imaging (BI)(62-64) and 
fluorescence imaging (FI) are the major forms of optical imaging (65-67). FI is capable of 
detection of surface fluorescence signals. These fluorescent molecules could be inherently 
existed in animal, such as interacting with fluorescence protein as a reporter; or to use 
modified fluorescent nanoparticles known as quantum dots as a tracer to track interested 
biomarkers. 
The inherent limitation of OI is imaging depth due to low penetration of light through the tissue. 
Although attenuation of fluorescence signal is a limitation for all optical imaging approaches, 
the superiority of FI methods including high sensitivity, high resolution, and the possibility of 
various design of tracers and signal amplification strategies make it as a promising imaging 
techniques in preclinical research.  
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2.3.3 Ultrasound Imaging 
Ultrasound has potential advantages in cardiovascular molecular imaging development as 
well. It is widely available and portable. Blood flow can be visualized easily and non-invasively 
by Doppler methods. Achieving molecular targeted imaging mainly is contributed by the 
development of microbubble contrast agents. All the contrast agents have in common the 
feature that they are micro-sized particles, which produce an ultrasound signal in response to 
an ultrasound field. Most commonly, the microbubbles are composed of perfluorocarbon or 
nitrogen gas encapsulated by shells made of phospholipid, liposome, or biodegradable 
polymers the capability to image cellular activity and the possibility of molecular targeting using 
labeled microbubbles (68-73). The modified microbubble are targeted to specific molecules, 
which present on the cell/tissue surface of interest. For ultrasound molecular imaging of 
atherosclerosis, targeting strategies for microbubbles exploit either the shell characteristics for 
attachment to activated leukocytes within inflamed vessels, or specific targeting by conjugation 
to inflammatory molecules on the active endothelium overlying atherosclerosis plaque (74). 
However, ultrasound’s poor resolution, inadequate quantitative data, and much reliance on 
operator experience limit its use in identifying vulnerable plaques. 
 
2.3.4 Nuclear imaging  
Currently, positron emission tomography (PET) and single photon emission computed 
tomography (SPECT) have been under evaluation for imaging vulnerable plaques by detecting 
inflammatory activity both in human and animal studies.  
Especially PET imaging shows great superiority in cardiovascular molecular imaging, it is 
performed in terms of injection of radiolabeled imaging probes to assess the function and 
activity in different disease by assessing the radiotracer’s accumulation. Unlike another 
conventional imaging (eg, radiography and computed tomography that characterizes the 
anatomy of disease-zone (eg, luminal diameter, plaque size), nuclear imaging techniques have 
been validated to visualize cellular-scale events (eg, protein regulation, molecular 
metabolism), which is able to reveal disease processes.  
Numerous biomarkers correlated to metabolic or pathological progression in vulnerable plaque 
have been investigated as imaging target, such as matrix metalloproteinase (MMP) using 
MMP inhibitors; macrophage apoptosis with  technetium-99m-labeled annexin-V, 18F-galacto-
RGD, which targets αvß3-integrin for evaluating angiogenesis within the plaque as well as 
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fluorodeoxyglucose (18F-FDG) commonly used to evaluate inflammatory activity within the 
plaque (82). Although 18F-FDG PET visualizes plaques inflammation nicely and a large 
number of studies demonstrated that 18F-FDG accumulation in atherosclerosis correlates with 
the macrophage density in plaques, some questions still remain with respect to if and how this 
inflammatory signal can be employed for predicting plaque rupture. Moreover, 18F-FDG-PET 
by detecting glucose uptake cannot reflect the inflammation directly and is less reproducible. 
Compared with other conventional diagnostic imaging techniques, PET imaging shows 
conspicuous superiority. It features high sensitivity, which contributed by radiotracers and PET 
crystal scanner. Therefore, PET has become one of the most frequently used molecular 
imaging techniques clinically. The hybridization of PET with CT and MR provides additional 
anatomical details to the lesions, allowing both functional and anatomical imaging.  
In the development of all cardiovascular nuclear imaging, the most crucial factor is the 
constructive design of sophisticated imaging tracers with high specificity for various molecular 
targets (Table 3) and sensitive for sensor detection.  
 
 
Table 3. Currently potential biomarkers as targets for nuclear medical imaging of 
atherosclerosis 
Biological process Category Specific biomarker and radiotracers 
Angiogenesis Endothelium ανβ3_68Ga-DOTA-RGD, 18F-Galacto-
RGD(61) 
Apoptosis Cell membrane Annexin A5_99mTc-annexin(75) 
Cell adhesion Endothelial surface 
receptors 
VCAM-1_18F-4V 
Macrophage/ 
Lymphocyte activity 
Surface receptors Somatostatin receptors_68Ga-
DOTATATE,Translocator protein 
(TSPO)_11C-PBR28; 
Metabolism Hexokinase, GLUT-1_18F-FDG 
Proteases MMP_124I-HO-MIP (CGS 27023A)_ 18F-
MMPI 
Thrombosis Platelet glycoprotein llb/lla 
receptor fibrin 
P-selectin_99mTc-Fucoidan,99mTc-
apcitide  
GLUT-1: glucose transporter-1, MMP: matrixmetalloproneinase, MMPI: matrixmetalloproneinase 
inhibitor, VCAM-1: vascular adhesion molecule-1, 18F-FDG: 2-deoxy-2-18F-fluoro-D-glucose, 
DOTATATE: DOTA-(Tyr3)-octreotate, 11C-PBR28: N-(2-methoxybenzyl)-N-(4-phenoxypyridin-3-
yl)acetamide (72 – 80) 
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In our studies, three PET tracers were evaluated in inflammation of atherosclerosis. To 
examine macrophage density within the plaques, we used 68Ga-DOTATATE and 18F-FDG; to 
examine activity of plaque, we detected the inflammatory indicator, P-selectin, on the 
endothelium overlying plaques by 68Ga-Fucoidan PET. 
 
18F-FDG PET 
In cardiovascular disease,  18F-FDG has proven to be useful in varied clinical fields including 
diagnosis, prediction and measurement of treatment effectiveness in myocardial infarction 
(76,77), and atherosclerosis (53,78-87) making it one of the most commonly used probes in 
cardiac PET imaging. Because 18F-FDG is a glucose analogue, cells participating in the 
inflammatory process must use glucose as energy supplier. Macrophages can also metabolize 
free fatty acids, this needs oxygen to generate adenosine triphosphate, whereas glucose 
metabolism does not. Therefore glucose is the major substrate for macrophages resident in 
plaque (88,89).  18F-FDG uptake is affected by several factors: the expression amount of 
GLUTs at the cell membrane, the hexokinase enzyme activity (90), and the rate of 18F-FDG 
dephosphorylation. Uptake of 18F-FDG in macrophages depends on the glucose concentration 
and the degree of macrophage activation (91). In ordinary monocytes, GLUT-3 expresses with 
higher concentrations than GLUT 1; but the insulin-sensitive GLUT 4 subtype is not detectable 
significantly. Activation of cells up-regulate both GLUT 1 and 3 expression. Furthuremore, 
macrophages produce a massive amount of hexokinase during inflammatory stimulation 
(92,93). However,  18F-FDG also accumulate at other plaque cell types, including endothelial 
cells (94). For another important clinical trail, diabetic patients with high risk of the 
complications of atherosclerosis are related important, since the effect of hyperglycemia on 
plaque 18F-FDG uptake should be considered. Theoretically,  18F-FDG accumulation can be 
diminished by hyperglycemia, due to competitive uptake between 18F-FDG and glucose. 
However, cell culture experiments and murine studies suggest that moderate hyperglycemia, 
does not adversely affect 18F-FDG uptake in inflammatory cells (95-97). Reproducibility of 
atheroma imaging with 18F-FDG still remains challenging, in those with high blood glucose at 
the time of imaging compared with hypoglycemic patients. 
Animal models of atherosclerosis have been used to explore the basis of vascular focal 18F-
FDG uptake. The first article demonstrating that 18F-FDG arterial uptake is related to  
atherosclerosis was reported in 1996. Tawakol et al (98) reported that although 18F-FDG 
uptake correlated strongly with macrophage infiltration. The most inflamed areas of plaque 
accumulated almost 20 times more 18F-FDG than control arteries. And there is no confirmed 
association between 18F-FDG uptake and plaque size, luminal stenosis, or the density of 
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plaque smooth muscle cells. The related studies suggest that the metabolic signal in plaques 
is predominantly due to the presence of macrophages. Additionaly, an autoradiographic 
assessment demonstrated enhanced 18F-FDG uptake after cholesterol feeding in both wild-
type (75) and ApoE  mice (95,99-101). 
In clinical studies, first prospective 18F-FDG -PET study to quantify atherosclerotic 
inflammation in atherosclerosis was from Rudd and colleagues (55). They found increased 
18F-FDG uptake at carotid artery lesions with severe symptom from patients with transient 
ischemic attack (Fig. 3). In corresponding ex vivo studies, accumulations of deoxyglucose 
within macrophage-rich areas of the excised carotid plaques were detected. They also showed 
enhanced focal 18F-FDG uptake in the culprit vertebral arteries of patients with symptomatic 
posterior territory stroke(102). Nowadays, 18F-FDG -PET has been investigated from the 
carotid and vertebral arteries to the aorta and iliac and femoral arteries (54,82,103,104). A 
significant correlation between 18F-FDG uptake and plaque inflammation has been 
demonstrated in clinical investigations. Nevertheless, 18F-FDG -PET imaging for coronary 
artery still remains changeling owing to significant myocardial uptake of 18F-FDG. The major 
obstacles include the myocardium uptake 18F-FDG actively under normal condition and 
considerable cardiac motion. In spite of challenges and inherent limitations, some groups have 
reported 18F-FDG accumulation is correlated with symptomatic coronary lesions (86,105-108). 
Consequently, increased 18F-FDG PET is approved with capability to detected activated 
macrophage within the plaque. And since an abundance of invading macrophages causes 
inflammation that makes plaques vulnerable to rupture, thus, 18F-FDG -PET imaging of 
macrophages is effective for diagnosing unstable plaques in murine atherosclerotic lesions. 
Since glucose metabolism is up regulated in activated macrophages,  18F-FDG has been used 
widely for preclinical and clinical studies. 
 
68Ga-DOTATATE PET  
Due to its ability to provide both structural and functional informations,  18F-FDG PET/CT holds 
great potential in the evaluation of vulnerable plaques. As inflammation detection has become 
the major concept in atherosclerosis PET/CT imaging, a more specific tracer is still to be 
found. (1,4,7,10-tetraazacyclododecane-N,N′,N″,N′″-tetraacetic acid)-d-Phe1,Tyr3-octreotate 
(DOTATATE) labeled with a generator-derived positron-emitting isotope Gallium-68 (68Ga) 
selectively binds to somatostatin receptor 2 (SSTR2). 68Ga-DOTATATE is routinely used for 
staging and restaging of neuroendocrine tumors (109)，and often followed by peptide receptor 
radionuclide therapy (PRRT) with 177Lu-DOTATATE (110,111). Importantly, SSTR-2 was also 
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found specifically expressed and upregulated on human macrophages (112-114), suggesting 
that SSTR-2 could be an important target for molecular imaging and therapy in 
atherosclerosis.  For several reasons, assessment of the up-regulated somatostatin receptors 
in vascular inflammation using specific somatostatin receptor radiotracers such as 68Ga-
DOTATATE, 68Ga-DOTATOC or 68Ga-DOTANOC may be superior to established 18F-FDG for 
atherosclerosis imaging: There are more specific for inflammation, and lacks myocardial 
uptake making it better suited for visualizing coronary arteries. Recently, 68Ga-DOTATATE-PET 
was proven to be a more specific alternative to the assessment of macrophages with PET/CT 
has been published (115,116).  
 
Imaging of P-selectin  
P-selectin is an adhesion molecule, which is highly expressed on the surface of active 
endothelium and platelets. It plays a pivotal role in recruiting leukocytes to the sites of injury 
(34,117,118). This interaction is mediated by P-selectin glycoprotein ligand 1 (PSGL-1), 
expressed by monocytes, neutrophils and platelets (119,120). Most active atherosclerotic 
lesions remain undetected until plaque rupture and thrombosis occur. A previous study found 
that inflamed atherosclerotic plaques have a strong expression of P-selectin on the overlying 
endothelium, but much less in normal arterial endothelium or in endothelium overlying inactive 
fibrous plaques (121). Consequently, P-selectin is thought to be an effective biomarker for 
assessing the bioactivity of active plaques.  
Fucoidan is a synthetic Sialyl-LewisX (sLeX) mimic, which is the natural ligand of P-selectin 
and is found on leukocytes (122,123). It is mainly derived from brown seaweed with an 
efficient binding of P-selectin as well (124). In previous studies, a high specific affinity of 
fucoidan for P-selectin was confirmed (124). Since fucoidan exhibits a great potential as a 
targeting probe, and PET with ability to do absolute quantitation possesses more investigative 
significance as compared to SPECT (Fig. 5) (125).  
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3.  BACKGROUND AND AIM OF THE PHD-THESIS  
Cardiovascular diseases remain the leading cause of mortality and morbidity worldwide. 
Rupture of atherosclerotic plaque accounts for approximately 70% of fatal acute myocardial 
infarction and sudden heart deaths.  
Noninvasive diagnosis of vulnerable plaque still remains a great challenge and a huge 
research prospect, which triggered us to investigate the feasibility of PET imaging on the 
evaluation of atherosclerosis. Molecular imaging of inflammation in atherosclerosis could 
provide a promising diagnostic tool for identifying vulnerable atherosclerotic plaque or early 
detection of inflammatory endothelium at risk in vivo. However, a specific imaging tracer for 
clinical applications has not been developed at yet. The aim of this work, was to assess the 
potential of novel PET imaging probes associated with intra-plaque inflammation on animal 
models and in human respectively. 
In our retrospective studies, we try to evaluate inflammation in the plaques. Both animal and 
translated human studies were performed.  
The purpose of animal study was to assess 68Ga-DOTATATE and 68Ga-Fucoidan on ApoE-/- 
mice with severe plaques. 68Ga-DOTATATE micro-PET was performed to detect infiltrated 
macrophage within the plaques. And 68Ga-Fucoidan micro-PET was performed to present P-
selectin expression on the endothelium overlying the plaques, in order to evaluate 
inflammatory activation on the plaques. 
The purpose of our human study was to evaluate inflammatory activity within the 
atherosclerotic plaques by 68Ga-DOTATATE PET imaging. The relationship of focal vascular 
68Ga-DOTATATE uptake to commonly known risk factors for cardiovascular disease and 
calcification were correlated. 18F-FDG, as most commonly used radiotracer, has already been 
assessed by several groups (57,105,126). We also validate the correlation to vascular 18F-
FDG uptake and compared with 68Ga-DOTATATE, We collected initial evidence from a 
retrospective analysis to characterize and modulate atherosclerotic plaque biology of oncology 
patients. 
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4.  ANIMAL STUDIES 
Evaluation	  of	  68Ga-­‐DOTATATE	  and	  68Ga-­‐Fucoidan	  on	  	  Apoliprotein	  E	  
knockout	  mice	  with	  atherosclerosis.	  
4.1  Materials and Methods 
Animal models and preparation 
Animal care and experiments were in compliance with the German animal protection law and 
were approved by the local district government of Unterfranken (AZ: 55.2-2531.01-19/07). 
Female apolipoprotein E (ApoE)-/- mice (n=8) were studied at the age of 50 weeks. Mice were 
fed high-cholesterol diet from age of 8 weeks, which is known to result in severe 
atherosclerotic plaques. The experiments were conducted at room temperature (RT). Mice 
were anesthetized during all procedures (isoflurane 2% to 2.5%, Baxter). Advanced 
atherosclerotic plaques were confirmed by histology. Non-atherosclerotic C57 mice (n=3) were 
studied as control group. 
Cell culture  
Murine macrophages/monocytes digested from fiv=\e mice spleen and lymph node maintained 
in RPMI 1649 medium supplemented with 10% heat-inactivated FCS, non-essential amino 
acids, 1mM sodium pyruvate, 100 U/ml and 100 µg/ml streptomycin, 2 mM L-glutamine and 30 
µM mercaptoethanol (all from Gibco). Cells were incubated overnight at 37°C and 5% CO2 in 
the presence and absence of 10 ng/mL LPS (Sigma). Upregulation of IL-6 protein level in 
culture supernatants was confirmed by Enzyme-linked immunosorbent assay (ELISA) at time 
point of 50h after LPS stimulation (supplementary Fig. 1). In order to prove SSTR-2 expression 
on endothelium, the murine endothelial cell line b.END.3 was purchased from American type 
Culture Collection. The adherently growing cells were cultivated under standard condition at 
37°C in a humidified 95% air/ 5% CO2 incubator, maintained in the complete growth medium. 
It mainly including Dulbecco's Modified Eagle's Medium (DMEM) (Gibco), supplemented with 
10% fetal calf serum (Gibco), 100 U/ml penicillin and 100 µg/ml streptomycin. The b.End.3 
cells were used at passages 25 to 30 for 68Ga-Fucoidan study. To activate inflammation, 
bEnd.3 cells were treated with 1 µg/ml of LPS (E. coli. 026:B6, Sigma) for 48 hours1. 
Subsequently, stimulated and non-stimulated b.End 3 cells were lysed for westernblot 
analysis. 
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Western blot analysis for the expression of SSTR-2 and P-selectin 
For analyzing of SSTR-2 expression, stimulated and non-stimulated macrophage were lysed 
in 100 µL ice-cold lysis buffer, the lysates were centrifuged at 12,000g at 4°C for 5 min to 
remove cellular debris. The supernatant was collected. 40 µL of supernatant containing the 
cell total proteins was separated by 10% sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) and transferred to nitrocellulose membrane (semidry western 
blot). After blocking with TBST containing 5% nonfat dry milk for 1h, the membrane was further 
incubated with 5ml TBST/5% nonfat dry milk solution containing 5 µL rat anti mouse SSTR-2 
primary antibody (ab9550, Abcam) for 24h at 4°C. After washing three times, the membranes 
was incubated with 5mL TBST solution containing 5 µL HRP-labeled goat anti rat IgG 
secondary antibody (Santa Cruz) for 1h.  
For P-selectin expression analysis, stimulated and non-stimulated b.End 3 endothelial cell 
were lysed in 100 µL ice-cold protein extraction reagent type 4 lysis buffer (Sigma-Aldrich), the 
lysates were centrifuged at 12,000g at 4°C for 5 minutes to remove cellular debris. The 
supernatant was collected. 40 µL of supernatant containing the total cell proteins was 
separated by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
and transferred to nitrocellulose membrane (semidry western blot). After blocking with TBST 
containing 5% nonfat dry milk for 1h, the membrane was further incubated with 5ml TBST/5% 
nonfat dry milk solution containing 5 µL rat anti mouse P-selectin primary antibody (antibody 
online) for 24h at 4°C. After washing three times, the membranes were incubated with 5mL 
TBST solution containing 5 µL HRP-labeled ECL anti-mouse IgG secondary antibody (GE 
Healthcare) for 1h. The immunoblot were developed using the ECL detection system (GE 
Healthcare).  
Histology and immunochemistry 
In 68Ga-DOTATATE study, for immunofluorescence staining 8 µm aortal sections were dried at 
room temperature and fixed in ice-cold acetone, washed in PBS buffer and incubated with 3% 
goat serum to avoid unspecific binding. Rat anti mouse CD68 monoclonal antibody 
(MCA1957, 1:75, AbD Serotec) was given for 90 min visualized by goat anti rat biotinylated 
secondary antibody (BA 9400, (1:300) Vector Laboratories, Burlingame, UK) for 30 min and 
Streptavidin–FITC (SA-5001, (1:100) Vector) for 30 min in green. After blocking with 
Avidin/Biotin blocking Kit (SP-2001, Vector) primary antibody against SSTR-2, rabbit anti-
mouse (ab9550, Abcam) in dilution of 1:100 was incubated over night at 4°C. Biotinylated goat 
anti rabbit (BA-1000, (1:300) Vector) and Streptavidin Alexa Fluor 546 (S11225, (1:100), 
Invitrogen) showed red colour of the somatostatin receptor. DAPI (1:1000, Merck) was used to 
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stain nuclei in blue. All images were conducted using a conventional fluorescence microscope 
(Zeiss Axiovision, Zeiss, Oberkochen, Germany).  
For immunohistology the sections were fixed in ice-cold acetone followed by 20 min treatment 
with 0.3% hydrogen peroxide/methanol to inhibit endogenous peroxidase. Subsequently, 
sections were blocked with Avidin/Biotin Blocking Kit (Vector S 2000, Vector Laboratories, 
Burlingame, UK) in rabbit serum and incubated with the primary antibody CD68 (rat anti 
mouse, 1:75, AbD Serotec) at 4°C over night. After washing with PBS, the sections were 
incubated with the biotinylated secondary antibody (rabbit anti rat, BA-4001, Vector) for 1 hour, 
washed in PBS and stained with ABC KIT (Vectastain, PK-6100) for 30 min. Visualization was 
performed with Diaminobenzidine (DAB) (abcam, ab675) for 5 minutes. The reaction was 
blocked with water; slides were counterstained with Hematoxylin, dehydrated in ethanol/xylene 
and mounted with Entellan Mounting Medium (Merck). For the demonstration of the plaque 
morphology we used haemalaun & eosin (H&E) staining according to Mayer.  
In 68Ga-Fucoidan study, after 68Ga-Fucoidan PET, Aortas were excised and frozen in 
Tissue-Tek O.C.T Compound (Sakura Finetek Europe B.V., Alphen aan den Rijn, The 
Netherlands) on dry ice, sliced in sequential longitudinal sections (n=300) and transverse 
sections (n=200) of 8 µm and 20 µm at -22°C (Leica Cryotome CM1850, Leica Microsystems) 
and mounted onto microscope slides.   The 20 µm sections underwent autoradiography and 
were apposed to an imaging plate over night for autoradiography. Autoradiographic images of 
longitudinal sections mainly included descending aorta, abdominal aorta, they were obtained 
in order to compare the uptake of activated and in inactive plaques. Transverse sections 
mainly include right and left subclavian artery, brachiocephalic artery, ascending aorta arch of 
aorta and part of descending aorta, Autoradiographic images of these arteries were used to 
correlate tracer’s uptake with anatomic MR imaging.  The 8 µm sections were used for staining 
with H&E to demonstrate morphology and for immunohistology. P-Selectin primary antibody 
(ABIN670131, Antibodies online, Aachen, Germany), was used for visualization of early 
atherosclerosis, followed by a biotinylated secondary antibody (BA-1000, Vector Laboratories, 
Burlingame, UK) and streptavidin (ABC KIT, PK-6100, Vector Laboratories, Burlingame, UK) 
and stained with Diaminobenzidine (DAB substrate KIT, abcam ab94665, Cambridge, U.K.). 
The sections were counterstained with Hematoxylin, dehydrated in Ethanol and Xylene and 
mounted with Entellan (Merck 1.07960, Darmstadt, Germany). For immunofluorescence 
double staining the sections were incubated with primary antibody against P-selectin 
(ABIN670131, rabbit anti mouse, Antibodies online, Aachen, Germany), and vWF (ab11713, 
sheep anti mouse, Abcam, Cambridge, U.K.) or CD68 (MCA1957, rat anti mouse, 
AbDSerotec , Düsseldorf, Germany) as secondary primary antibody. After a two step staining 
procedure with biotinylated secondary antibody (BA-1000 against P-selectin, BA-6000 against 
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vWF, and BA-9400 against macrophages, all Vector Laboratories, Burlingame, UK) and 
streptavidin in two different fluorescent colours, Alexa Fluor 546 (S11225, invitrogen, 
Karlsruhe, Germany) and (Streptavidin-FITC, SA-5001 Vector Laboratories), 4’,6-diamidino-2-
phenylindole (DAPI) was used for nuclear staining. Images were taken with a Zeiss Axioskop 2 
plus Fluorescence Microscope.  
For Sudan IV staining, aortae were fixed in 4% formaldehyde. The aortae were opened 
longitudinally, from the aortic arch to the iliac arteries. The primary incision followed the inner 
curvature of the arch. To obtain a flat imaging, an incision was made along the outer curvature 
of the arch. The aortae were then pinned on a black wax surface using stainless steel pins 
0.25 mm in diameter. After being rinsed with water, the aorta was exposed to isopropanol 
(60%) for 2 min, followed by 35 minutes of staining with a Sudan IV solution, which contained 
5 grams of Sudan IV, dissolve into 500mL acetone & 500mL 70% EtOH. The excess stain was 
removed with 80% EtOH and running water subsequently. Whole aortas were imaged using a 
microscope with a digital camera (Leica). 
 
Statistical analysis 
Statistical Package for Social Sciences (SPSS version 11.0; SPSS Inc.) was used for 
statistical analyses. Continuous variables with a normal distribution were recorded as mean ± 
standard deviation (SD). Group comparisons were made using two-tailed T-test, P-value of 
less than 0.05 was considered statistically significant. 
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4.1.1 ANIMAL STUDY I: Macrophage characterization of atherosclerosis:  
68Ga-DOTATATE ex-vivo detection in mice 
Preparation of 68Ga-DOTATATE  
Preparation of 68Ga-DOTATATE has been established in the department of nuclear medicine 
for clinical applications. 68Ga-DOTATATE used in the present study was synthesized on a 
computer-assisted synthesis-module (Scintomics, Fürstenfeldbruck, Germany). 68Ga for 
radiolabeling was eluted in form of 68GaCl3  with 0.1 M HCl from a 68Ge/68Ga-generator 
(Obninsk, Russia) into a reactivial (Thermo Scientific, Langenselbold, Germany), containing 10 
µg of DOTATATE and HEPES-buffer. After 10 min at 95 °C, the crude product was separated 
via a Waters-Sep-Pak-C18 cartridge (Waters, Eschborn, Germany), diluted with 0,9 % NaCl 
and filtrated through a 0.22 µm sterile filter (Millipore, Cork, Ireland) into a sterile vial (IBA, 
Berlin, Germany) for biological evaluation.  
Radiochemical purity, as assessed by gradient HPLC (eluent A: 0.1 % TFA in H2O, eluent B: 
0.1 % TFA in acetonitrile, flow rate: 0.7 ml/min, column: Nucleosil 100-5 C18 125x4.6 mm, 
gradient: nonlinear 0 % to 100 % solvent B in 15 min; Scintomics, Fürstenfeldbruck, Germany) 
and TLC (eluent: 0.1 M citric acid, stationary phase: ITLC-SG stripes (Varian, Lake Forest, 
USA); measurement time: 1 min; miniGITA, raytest, Straubenhardt, Germany) was >99%. The 
specific activity of the injection solution amounted 50 MBq/µg.  
 
Purification of monocytes/macrophages 
Erythrocyte-depleted spleen cells were stained in fully-supplemented RPMI medium with anti-
CD11b-PE (clone M1/70, BD Biosciences), anti-Ly-6G (clone 1A8, Biolegend) and anti-CD11c-
eFluor 450 (clone N418, eBioscience). After a final washing step, cells were resuspended in 
RPMI medium and sorted with FACSAria III cell sorter (BD Biosciences). Monocytic cells were 
defined as CD11bhigh, Ly-6G-, CD11c-. 
 
FACS analyze of SSTR-2 expression on leukocytes, endothelial cells and 
platelets. 
We used flow cytometry to measure SSTR-2 expression within the arterial wall. Since cluster 
of differentiation 31 (CD31) is platelet endothelial cell adhesion molecule (PECAM), murine 
endothelial cells line (b End.3 ) was confirmed by flow cytometry separately. Samples of the 
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aorta (n=3) were dissected under a microscope. Digestion: collagenase type 2 and protease 
type XIV (0.895 mg/ml and 0.5 mg/ml respectively) in PBS the aorta was incubated for 1 h at 
37°C. blood were collected as well. Cells were pre-blocked with anti-Fcγ receptor III/II 
monoclonal antibody (mAb) (clone 2.4G2) and 5% rabbit serum for 15 minutes at 4°C for 15 
minutes and subsequently stained with anti-CD41(biolegend), anti-CD3ε(biolegend), anti-
CD11b (ebioscience), anti-Ly-6G (biolegend) and anti-SSTR-2 (Abcam). To examine the 
SSTR-2 expression on endothelial cell, b.End.3 cells were stained with anti-CD31 (biolegend), 
after washing, cells were blocked with 5% goat serum and anti-SSTR-2 mAB was detected via 
polyclonal biotinylated goat anti-rabbit mAB. At the end, we added Streptavidin-FITC (dilution 
1:500). The cells were washed in FACS buffer between every step three times. Every 
incubation step took 15 minutes. Measurements were performed on LSRII (BD biosciences). 
For plots FloJo software (treestar) was used. 
 
Autoradiographic analysis 
ApoE-/- mice (n=5) were sacrificed one hour after injection (15±1.5 MBq); accumulation of 
68Ga-DOTATATE in the aorta was assessed using 20 µm sections (n=100) of sample tissues 
with a digital autoradiography system (CR 35 BIO, Buerr Medical, Bietigheim Bissingen, 
Germany).  Region of interests (ROI) analysis of images was performed to determine activity 
ratios for the plaque area relative to the non-plaque area. Aorta sections (n=60) from non-
atherosclerotic C57 mice (n=3) were also assessed as well, In order to evaluate specificity of 
68Ga-DOTATATE uptake, sections from non-injected ApoE-/- mice were incubated with 
antibody against SSTR-2 for 2 hours before incubating with 68Ga-DOTATATE in vitro at room 
temperature. All images were processed by two-Dimensional median filtering algorithm 
(Matlab 7.0, Mathworks Massachusetts, U.S) before analysis.  
 
 
 
  
Animal	  Studies:	  Materials	  and	  Methods	  -­‐-­‐-­‐	  68Ga-­‐Fucoidan	  Study	  
	   27	  
4.1.2 ANIMAL STUDY II: Targeting P-selectin by Gallium-68 labeled 
Fucoidan PET for non-invasive characterization of vulnerable plaques: 
Correlation with in vivo 17.6T MRI 
Preparation of 68Ga-Fucoidan 	  
Fucoidan was purchased commercially from Sigma-Aldrich (Deisenhofen, Germany) and was 
used without further purification for radiolabeling. The synthesis of 68Ga-Fucoidan was carried 
out in the in-house radiopharmacy using a computer-assisted synthesis-module (Scintomics, 
Fürstenfeldbruck, Germany). 68Ga for radiolabeling was eluted with 0.1M HCl in form of 
68GaCl3 from a 68Ge/68Ga-generator (Obninsk, Russia). The labeling procedure was optimized 
concerning the amount of Fucoidan, reaction time and reaction temperature. Optimization led 
to the following standard labeling protocol: 68GaCl3 (typically 500- 750 MBq) was eluted with 
0.7 mL of 0.1 M HCl directly in a reaction vial (Thermo Scientific, Germany) containing 300 µL 
of 0.1 M acetate buffer (pH = 4.8) and 50 µg (50 µl) of Fucoidan from a solution consisting of 
1.0 mg Fucoidan/1mL saline). The solution was allowed to react for 10 min at 90°C, following 
by a purification of the crude product on a Waters-Sep-Pak-C18 cartridge (Eschborn, 
Germany), diluted with PBS (pH 7.0; Braun) and filtrated through a 0.22µm sterile filter 
(Millipore, Cork, Ireland) into a sterile vial (IBA, Berlin, Germany) for biological evaluations. 
Quality control and in vitro stability were determined by HPLC (Shimadzu, Duisburg, Germany) 
using 0.01 M aqueous NaOH/acetonitile (9:1) at flow rate of 1.0 ml/min as mobile phase on a 
column (Dionex CarboPak-PA10, 250x4.5 mm, 10 µm) as stationary phase. Additionally, a 
thin-layer chromatography (TLC) was performed, applying the analyte to an ITLC-SG strip 
(Varian, Lake Forest, USA) using 0.1M sodium citrate as mobile phase. A TLC-scanner (mini-
GITA®, Raytest, Straubenhardt, Germany) was used to image the TLC strips. 
  
Cell uptake of  68Ga-Fucoidan 
The cellular uptake of 68Ga-Fucoidan was tested on bEnd.3 endothelial cells with and without 
LPS stimulation.  Radioactive substances which were diluted to 1.5*106 counts per minute 
(cpm) / 1mL culture medium were added to the 1*106 attached cells and incubation in a 
humidified 95% air/ 5% CO2 incubator for different time intervals (5min, 15min, 30min, 45min,) 
at 37°C. After incubation, interactions between cells and tracers were interrupted by placing 
samples on ice. Then, the cells were washed thrice with cold PBS (0.1mol/L, PH 7.4), and 
trypsinized in 0.5mL for measurement.  Cellular uptake was measured using a high-energy 
gamma counter (Wallac, Rodgau, Germany). 
Animal	  Studies:	  Materials	  and	  Methods	  -­‐-­‐-­‐	  68Ga-­‐Fucoidan	  Study	  
	   28	  
 
Cell viability 
To determine apoptosis induction, endothelial cells were treated with Fucoidan at 
concentration of 1µg/ml, 5µg/ml, 10µg/ml, 20µg/ml and 40µg/ml for 48 hours, subsequently 
harvested, and ready for apoptosis analysis. To determine the morphologic nuclear changes, 
phosphatidylserine exposure was determined using annexin V– pacific blue (BD Bioscience) in 
combination with 7aad (BD Bioscience). Harvested dual stained cells and subsequently 
analyzed by flow cytometry. The percentage of cellular apoptosis and necrosis was 
determined by examining 200 000 cells and counting the cells that were characterized by 
nuclear condensation and fragmentation. In experimental process, apoptosis induction 
experiments were performed in 24-well culture plates (Costar). Cultured as described above. 
Cells were treated with Fuciodan at concentration of 1µg/ml, 5µg/ml, 10µg/ml, 20µg/ml and 
40µg/ml for 48 hours, subsequently harvested, and ready for apoptosis analysis. To determine 
the morphologic nuclear changes, Phosphatidylserine exposure was determined using 
annexin V– pacific blue (BD Bioscience) in combination with 7aad (BD Bioscience). Cells were 
harvested, washed, incubated with annexin V– pacific blue and 7aad for 15 minutes in the 
dark. As control, unstained cells, cells stained with annexin V– pacific blue (no 7aad) and cells 
stained with 7aad (no AnnexinV- pacific blue) were prepared to assess as well. 
 
Animal studies 
ApoE-/- mice were used in our experiments. In order to induce development of severe 
atherosclerotic plaques, ApoE-/- mice were fed with a high cholesterol diet (1.25% cholesterol, 
7.5%cocoa butter, 7.5% casein) for 38 weeks starting at of age of 8 weeks To obtain mice 
with server atherosclerosis, all ApoE-/- mice were fed with Western diet (or 30 weeks at 
age of 4 weeks(127,128).  As controls, C57BL/6 mice were fed with normal chow. Severe 
atherosclerotic plaques in ApoE-/- mice were confirmed by histology (H&E staining). All 
experimental protocols were in compliance with the German animal protection law and were 
approved by the local district government of Unterfranken (AZ: 55.2-2531.01-19/07).  
 
Biodistribution of 68Ga-Fucoidan in ApoE-/- mice   
The biodistribution of 68Ga-Fucoidan was determined in ApoE-/- mice (46 weeks old, n=3). 
Mice were sacrificed 60 minutes after intravenous injection of the radiotracer (4.9±0.6 MBq), 
Animal	  Studies:	  Materials	  and	  Methods	  -­‐-­‐-­‐	  68Ga-­‐Fucoidan	  Study	  
	   29	  
and perfused with 50 µL of saline, blood, heart, lung, kidney, brain, bone, leg skeletal muscle, 
fat, skin, spleen and liver were harvested and weighted. Radioactivity was subsequently 
measured by high-energy gamma counter (Wallac, Rodgau, Germany).  
 
Magnetic resonance imaging 
In vivo high resolution MR imaging was conducted on a 17.6 T vertical bore MR system 
(Bruker Biospin GmbH, Germany), using a homebuilt radiofrequency coil (birdcage design, ID: 
27 mm). The images were acquired with an ECG-triggered and respiratory gated T1-weighted 
Multi-Slice-Multi-Spin-Echo-Sequence with following parameters: repetition time TR=1s; echo 
time, TE=9 milliseconds; bandwidth, 83 kHz; in-plane resolution 78µm × 78 µm; slice thickness 
0.6 mm; total acquisition time= 20 minutes (129). Images were analyzed with OsiriX DICOM 
(Osirix) viewer software. 
 
PET imaging 
68Ga-Fucoidan was administered intravenously into ApoE-/- mice  (7.7±1.3 MBq) (n=10) and  
C57BL/6 control mice (6.5±0.8 MBq) (n=6) under anesthesia with 1.5% isoflurane post MRI 
scan. For the control, six C57BL/6 mice were administered intravenously with 68Ga-Fucoidan 
(6.5±0.8 MBq). Imaging was performed from time point 50 minutes to 110 minutes (6 scans) 
after injection using a Siemens micro-PET system (Inveon) with a 10 minutes acquisition time. 
In order to better understand of influence of long blood half-life of 68Ga-Fucoidan, and correct 
localization of aorta wall, after the first in vivo emission scan, murine (both ApoE-/- and 
C57BL/6 mice) liver, lung, spleen, kidney, intestines, stomach were carefully removed under 
the dissection microscope, then the mice were re-scanned using the same protocol as in the 
first time, subsequently the blood within heart and aorta were wash out by PBS buffer,  and 
then scanned again for the third time using the same protocol. For the imaging reconstruction, 
OSEM2D algorithm was used. To quantify the 68Ga-Fucoidan uptake, all micro-PET scans 
were reviewed for anatomic localization and amount of focal uptake. Representative segments 
of large arteries were analyzed, aortic arch, descending thoracic aorta, and abdominal aorta. 
Regions of interest (ROIs) were drawn around the wall of the selected aortic segments. The 
mean standardized uptake value (SUV) was extracted for the final calculation of target-to-
background ratios (TBRs).  Background was determined by the mean SUV of six different 
ROIs in the foreleg muscle. Transverse, coronal and sagittal views were analyzed. The relative 
tracer uptake is characterized as the TBR and SUV respectively. Quantitative dynamic PET 
studies were performed In order to understand tracer kinetics; the PET imaging data was 
Animal	  Studies:	  Materials	  and	  Methods	  -­‐-­‐-­‐	  68Ga-­‐Fucoidan	  Study	  
	   30	  
acquired from tracer injection to 100mins after injection. In order to estimate in vivo specificity 
of 68Ga-Fucoidan, four apoE-/- mice were pre-injected of 1 mg sLeX mixed in 100µL PBS 
respectively. 
 
Ex vivo autoradigraphic study 
All ApoE-/- mice (n=6) were sacrificed after the PET scan. Accumulation of 68Ga-Fucoidan in 
the aorta was assessed using 20 µm sections of sample tissues with a digital autoradiography 
system (CR 35 BIO, Duerr Medical, Bietigheim Bissingen, Germany). Regions of interest 
(ROIs) were drawn to qualify activity ratios for the activated plaque areas relative to the 
inactivated plaque areas and the uptake ratios to the non-plaque were determined as well. In 
order to evaluate specificity of 68Ga-Fucoidan uptake, tissue sections (n=40) from ApoE-/- mice 
were incubated with sLex for 24 hours before incubation with 68Ga-Fucoidan in vitro at 4°C. 
Activated atherosclerosis were defined by intensive infiltration of blood-derived monocytes into 
arterial intima. Activated vulnerable plaques were characterized by thin fibrous cap and high-
density macrophage infiltration; fibrous plaques were classified as inactivated plaque; Fatty-
streak were classified as non-plaque lesions.	  
 	  
Animal	  Studies:	  Results	  -­‐-­‐-­‐	  68Ga-­‐DOTATATE	  Study	  
	   31	  
4.2 RESULTS  
 
4.2.1 ANIMAL STUDY I: Macrophage characterization of atherosclerosis:  
68Ga-DOTATATE ex-vivo detection in mice 
 
Flow cytometry of digested aortas & endothelial cells  
Results of flow cytometry are shown in Fig. 3. Somatostatin receptor 2 was found to be 
expressed at significant levels the macrophage/monocyte (CD11b+Ly-6G-) (60.4%), on small 
part of T-cells (CD3ε+ )(28.3%), but no expression on neutrophils (CD11b+Ly-6G+) (0%) and 
platelets (CD41+) (0.136%). Notably, SSTR-2 was found to be significantly expressed on 
bEnd.3 murine endothelial cells (CD31+) (97.2%) as well.  
 
Figure 3: Flow cytometric analysis of digested aorta from ApoE-/- mice (n=3) with atherosclerotic 
plaque. Cells were gated by different markers, neutrophils (CD11b+, Ly-6G+), Macrophages and 
monocytes (CD11b+, Ly-6G-), T-cells (CD3ε+), platelets (CD41+) and b End.3 endothelial cells (CD31+). 
Somatostatin receptors were detected expressed on most gated macrophages/monocytes (60.4 %), 
and part of gated T-cells (28.3%), but not detected on gated neutrophils (0%) and platelets (0.136%). 
Western blot analysis of SSTR-2 expression in macrophages/monocytes differentiated from mice spleen 
and lymph node. Cells were incubated in presence (+) or absence (−) of 10ng/ml LPS for 24h. 
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SSTR-2 expression on macrophages 
We found significant expression of SSTR-2 in macrophages at the protein level by western 
blot. We also assessed the dose-dependent effect of the expression of SSTR-2 in response to 
the LPS stimulation. Results showed SSTR-2 was detected both in induced and non-induced 
macrophages. Treatment of macrophages with 10 ng/ml of LPS for 24h did not affect  SSTR-2 
expression (Fig. 3). As an indicator for macrophage activation, IL-6 secretion was assessed in 
the presence of LPS (10ng/ml) and was found to be significantly increased (Fig. 4)  
 
 
Figure 4: ELISAs were performed to determine IL-6 levels as a marker of inflammation; Equal 
quantities of total protein were used. Data are expressed on pg/ml of for IL-6. 
 
Characterization of atherosclerosis 
Histological experiments demonstrated that all ApoE-/- mice in our studies had severe 
atherosclerotic plaques. All tissue section samples showed high specific uptake of 68Ga-
DOTATATE into atherosclerotic lesions by autoradiography (Fig. 5A, Fig.6A) as confirmed by 
macrophage-specific DAB staining (Fig. 5B) and H&E histological staining (Fig. 5-6). The 
uptake of plaque-area from each single ApoE-/- mouse was significant higher than the non-
plaque area (Fig. 5D).  
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Figure 5: Ex vivo imaging of excised aortic section from atherosclerotic ApoE-/- mice (n=5). (A) 
Autoradiographic visualization of the 68Ga-DOTATATE accumulation in aorta in an atherosclerotic 
plaque of an ApoE-/- mouse (section with 20 µm slice thickness); (B) H&E staining of adjacent-tissue 
section with 8 µm thickness. (C) Autoradiographic image and (D) H&E staining image of one negative 
control sample from three wild type C57 non-atherosclerotic mouse. (E) Ratio of plaque vascular uptake 
to non-plaque vascular uptake for 68Ga-DOTATATE from five ApoE-/- mice. * p<0.05. Figure 
demonstrates that 68Ga-DOTATATE accumulate in advanced atherosclerotic plaques which are marked 
by dotted line in H&E staining image, but few in the normal endothelium.  
 
 
Figure 6: Representative Ex vivo Imaging of excised aortic sections from one of atherosclerotic ApoE-/- 
mice (n=5). (A) Autoradiographic visualization of the 68Ga-DOTATATE accumulation in aorta in an 
atherosclerotic plaque of all mice (section with 20 µm slice thickness); (B) DAB staining and (E) H&E 
staining of adjacent-tissue sections with 8 µm thickness. The Fig. demonstrates that 68Ga-DOTATATE 
accumulate in atherosclerotic plaques. 
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Co-localization of the SSTR-2 and macrophages in plaques was confirmed by the 
immunochemistry (Fig. 7). Receptor blockage using monoclonal antibodies against SSTR-2 
resulted in a significant decrease of tracer accumulation in aorta, indicative of a high specificity 
of 68Ga-DOTATATE uptake for the assessment of SSTR-2 (Fig. 8). 
 
Figure 7: Representative immunohistological images from n=6 mice show the co-localization of SSTR-2 
signal and macrophages. A Immunofluorescence staining of macrophage (CD68 green) in the plaque. B 
Anti-SSTR-2 monoclonal antibody highlights the regions with strong SSTR-2 expression (red). C Cell 
nuclei stained with DAPI (Blue). D Overlay of three channels (merge), image is representative for the 
co-locatization of macrophages and SSTR-2, supporting the notion that macrophage may be identified 
by 68Ga-DOTATATE. Corresponding control images were shown. E Consecutive tissue sections were 
used for H&E staining.  No SSTR-2 and CD68 expression was detected in control images (data not 
shown). Combined with Fig.2 this Fig. demonstrated 68Ga-DOTATATE accumulates in areas of high 
macrophage content within atherosclerotic plaques of ApoE-/- mice. 
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Figure 8: Pre-incubation of monoclonal antibody against SSTR-2 inhibited uptake of 68Ga-DOTATATE in 
atherosclerosis plaque from ApoE-/- mice (n=3). (A) Autoradiography images show the lower uptake in 
the aorta pre-incubated with SSTR-2 targeted antibody. (B) Histology demonstrated the co-localization 
of atherosclerotic plaque with the area of increased 68Ga-DOTATATE uptakes by H&E staining.  
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4.2.2 ANIMAL STUDY II: Targeting P-selectin by Gallium-68 labeled 
Fucoidan PET for non-invasive characterization of vulnerable plaques: 
Correlation with in vivo 17.6T MRI 
	  
Synthesis of 68Ga-Fucoidan, in-vitro stability, and pharmacokinetics analysis 
For optimization of the radiolabeling conditions varying the amounts of the Fucoidan (10 – 250 
µg), reaction times (5 – 35 min) and different reaction temperatures (22 - 95°C) were tested. It 
was found that Fucoidan could be labeled with 68Ga at 90°C within 10 min using 100 µg of 
Fucoidan at pH 3.4. 68Ga-Fucoidan was obtained in an overall decay-corrected reaction yield 
of 90 ± 5% and 99% radiochemical purity. The total synthesis time including column 
purification on a reversed-phase cartridge and quality control were completed after 40 min. To 
determine the stability of 68Ga-Fucoidan in injectable solution, additional TLC was performed 
at 1, 2, 3 and 4h after radiolabeling. The radiochemical purity was still > 98% and thus 68Ga-
Fucoidan showed an excellent in-vitro stability in an injection solution (PBS) for further 
biological investigations. 
To assess the biodistribution of 68Ga-Fucoidan in mice, all data were corrected for decay and 
residual activity at the injection sites, the tracer uptake was expressed as the percentage of 
initial injected dose per gram of tissue after correction for decay (Fig. 9). Biodistribution are 
expressed as %ID/g; kidney=5.9±1.4, heart=5.7±1.3, spleen=4.1±0.7, liver=4.7±1.2, 
blood=16.8±3.2, bone=1.4±0.2, lung=3.1±0.9, brain=1.2±0.2, fat=0.9±0.1, muscle=0.8±0.1, 
skin=0.8±0.1. 
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Figure 9: Biodistribution analysis of 68Ga-Fucoidan in mice (n=3) was performed 60 minutes. After 
intravenous injection, Results are expressed as mean±SD. 
 
LPS enhanced 68Ga-Fucoidan cellular uptakes & Cell viability assessment 
Incorporation of 68Ga-Fucoidan into LPS-treated and non-treated bEnd.3 endothelial cells was 
determined using a high-energy gamma counter.  Compared with non-induced endothelial 
cells, LPS induced cells showed an approximate 2-fold increased uptake of 68Ga-Fucoidan 
(Fig.10A). The radioactivity incorporation in endothelial cells following a 30 minutes incubation 
at 37°C varied approximately 35% of the total loaded activity per 106 cells (522 - 546 cpm / 
1000 cells). We examined the effect on expression of P-selectin proteins in response to the 
inflammation inducer LPS. Results showed detectable up-regulation of P-selectin on LPS-
induced bEnd.3 cells compared with cells of untreated controls, which were confirmed by 
western blot (Fig. 10B). 
To determine whether Fucoidan is able to induce apoptosis, early passage endothelial cells 
were incubated with different concentration of Fucoidan in triplicate, the cells were dual-
stained with annexin-V-pacific blue and 7aad, subsequently analyzed by flow cytometry. 
Apoptosis as evaluated by the percentage of cells binding Annexin V and 7-AAD, dead cells 
ratio is 1.15% without incubation with Fucoidan while 1.73% after incubation of Fucoidan (40 
µg/ml) for 48hours. No significantly diminished cell viability was observed (Fig.10 C). In order 
to determine toxicity of Fucoidan in vivo, we injected intramuscularly a high dose of Fucoidan 
(5mg/kg/d during 3 weeks) into C57BL/6 mice (n=10), and no detectable side effects were 
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observed. Therefore, we demonstrated no significant cytotoxic effects were observed in high 
doses of Fucoidan. 
 
 
Figure 10: A, Effects of LPS on 68Ga-Fucoidan uptake, 68Ga-Fucoidan uptake were recorded at 5min, 
15min, 30min, 45min in bEnd.3 endothelial cells treated with and without LPS (1ug/mL) for 48 hours. B, 
Western blot of P-selectin protein expressed in LPS-treated (+LPS) and non-LPS-treated (-LPS) cells. 
GAPDH was used as an internal standard. C, bEnd.3 endothelial cells were incubated with 40 µg/ml 
Fucoidan. At time point of 48 hours the cells were stained with 7-AAD and annexin V-pacific blue 
followed by flow cytometry analysis. Representative flow cytometry image of cell apoptosis analysis, 48-
hour incubation with Fucoidan did not induce cellular apoptosis (Q1) and necrosis (Q3). 
 
Ex vivo detection of P-selectin expression on atherosclerotic plaques 
Pronounced uptake was observed in activated soft plaques, but less uptake in inactivated 
fibrous plaques, plaque morphology and activity were confirmed by H&E histological and DAB 
staining, representative autoradiography images are shown in Figure 11. 
Immunohistochemical staining of adjacent aorta sections indicated an enhanced P-selectin 
expression in soft atherosclerotic plaques with high-density macrophage interaction, but 
weaker expression in fibrotic plaques with low-density of macrophage. Enhanced expression 
of P-selectin and macrophage in the vulnerable soft plaque co-localized with increased uptake 
of 68Ga-Fucoidan indicated (Fig. 11).   
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Figure 11: 68Ga-Fucoidan accumulated at high P-selectin expressing and high macrophage density 
regions within the aorta. A, Representative autoradiographic image of the aorta of an apolipoprotein E-
deficient (ApoE-/- ) mouse on Western diet for 38 weeks. ROI (I) and ROI (II) were adjusted manually to 
obtain the SUV.  B(I), C(II), DAB staining of P-selectin and D(I), E(II), DAB staining of macrophages 
(CD68), which are respectively corresponding to the region I and region II in autoradiography. Stronger 
uptake was visualized at atheromatous plaques (ROI (I)), presenting dense foam cells while weaker 
uptake at fibrous plaques (RIO (II)). 
 
In the assessment of ex vivo accumulation of 68Ga-Fucoidan of each mouse, 10 tissue 
sections were analyzed by autoradiography, We studied 280 lesions, (150 activated lipid-rich 
plaque segments with high-density macrophage, 80 inactivated fibrous plaque segments with 
lower-density macrophage and 50 non-plaque area with fatty streak or healthy endothelium) 
which were selected according to histological test. The tracer uptake in activated soft plaque-
areas was higher than in inactivated fibrous plaque area (R=1.73±0.3, P <0.05) in each single 
ApoE-/- mouse, and also significant higher than in the non-plaque endothelial segments 
(R=2.35±0.4, P <0.01). Acute vascular inflammation model was developed, because 
endothelial dysfunctions are representatives of early stage and advanced stage of 
atherosclerosis. In brief, for acute vascular inflammation model, 1 mg/ml LPS in 100 µL PBS 
was intravenously injected into the C57/6 mice (40 weeks old n=6). Prior to radiotracer 
injection, mice were exposed to LPS for 24 hours. Ex-vivo autoradiographic assessment were 
performed to evaluate tarcer’s uptake. Higher uptake were observed at LPS-induced mice in 
comparison to non-induced control mice. (Fig. 12) 
Double-immunofluorescence staining revealed P-selectin expression on the endothelium 
overlaying soft inflamed plaques as indicated by vWF staining, and co-localization with 
macrophages within the activated plaque (Fig. 13).  
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Figure. 12: Representative autoradiography imaging two aortas from non-LPS induced mouse (A) and 
LPS induced mouse (B). Comparison of P-selectin immunohistological staining. C, D Corresponding 
DAB staining of section I and section II respectively. 
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Figure 13: Double staining of a representative thin-capped fibroatheroma with large necrotic core. P-
selectin (red) express in the endothelium overlying vulnerable plaque, von Willebrand factor (vWF) 
(Green) was used to indicate endothelium (A), CD68 staining for expression of macrophage (B); nuclear 
counterstain with DAPI (blue); Co-localization of P-selectin and vWF on the endothelium (A), and 
macrophages (CD68) were shown in merged image (B). 
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In vivo detection of P-selectin expression 
Dynamic PET studies determined that the optimum imaging time. Because of high level of 
radiotracer in the blood, and difficult localization of focal uptake at early time points, PET 
images (n=10) were acquired by collection of six frames in duration from 50 minutes to over 
100 minutes. Subsequent work showed that 60minutes to 70 minutes could be used without 
significant degradation of the arterial signal. Data from each of the frames is independently 
(Fig. 14). ROIs were assigned to the aortic arch, ascending aorta, descending aorta, and 
abdominal aorta on micro-PET images (n=20). Representative micro-PET images showed 
tracer accumulation in the atherosclerotic lesions at coronal view matching the Sudan IV 
staining (Fig.14).  
 
 
Figure 14: A, Representative atherosclerotic aorta of apoE-/- mouse fed with western diet for 40 weeks, 
micro PET images (six frames) were obtained from time points 50 minutes to 100 minutes after injection 
A. the presence of neutral lipid within the plaque were assessed by enfaces staining with Sudan IV. 
Arrows indicate neutral lipid stained plaques. B, The mean of target to background ration (TBR) value of 
aortal focal uptake at all time points, data are given as mean±SD. C, Mean standardized uptake value 
(SUV) of aortal focal uptake and leg muscle at all time points, data are given as mean±SD. D, Micro 
PET image shown obvious aortal uptake from time point 50 minutes to 100 minutes after injection, 
arrow indicate plaque and corresponding uptake of 68Ga-Fucoidan. Arrow signifies the presence of 
accumulation of 68Ga-Fucoidan at plaque. 	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Clear localized focal uptake of 68Ga-Fucoidan at time points of 60 minutes was detected in all 
apoE-/- mice with SUVmean=5.1±0.5, SUVmuscle=1.0±0.2, and TBRmean =5.1±0.8. The 
specific accumulation of radiotracer at atherosclerotic plaques was also correlated with 
histological lipid staining, noninvasively with 17.6T MRI. The representative micro-PET, high-
resolution MRI and autoradiography of aorta arch section showed a good agreement between 
uptake of 68Ga-Fucoidan and plaque vulnerable morphology (Fig. 15). No specific vascular 
uptake was detected at control mice. Significant uptake in the myocardium was observed in all 
apoE-/- mice. Further representative noninvasive images of brachiocephalic artery section are 
given in the figure 16. 
 
 
Figure 15: Representative noninvasive images, aortic arch from an ApoE-/- mouse on Western diet for 
38 weeks. All red arrows indicate regions of interest.  In vivo ultra-high-field MRI of the aortic arch using 
an ECG-triggered Multi-Slice-Multi-Spin-Echo sequence. Micro-PET imaging at transverse view 
suggesting specific uptake of 68Ga-Fucoidan by the plaque. Corresponding autoradiography image of 
the aortic arch. H&E staining of corresponding plaque section. Thin cap (bright outer layer), large lipid 
core (dark inner part) and calcification (bright inner part) of plaque were characterized on MR images 
and histology, whereas in accordance with high uptake of 68Ga-Fucoidan confirmed by micro-PET and 
autoradiography. 
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Figure 16: Representative noninvasive images, brachiocephalic trunk from an ApoE-/- mouse on 
Western diet for 38 weeks. All red arrows indicate regions of interest.  A, In vivo ultra-high-field MRI of 
the aortic arch using an ECG-triggered Multi-Slice-Multi-Spin-Echo sequence.B, Micro-PET imaging at 
transverse view suggesting specific uptake of 68Ga-Fucoidan by the plaque. C, Corresponding 
autoradiography image of the aortic arch. D, H&E staining of corresponding plaque section. Thin cap 
(bright outer layer), and large lipid core (dark inner part) of plaque were characterized on MR images 
and histology, whereas in accordance with high uptake of 68Ga-Fucoidan confirmed by micro-PET and 
autoradiography. 
 
In vivo and ex vivo blocking studies 
Receptor blockage using sLex the nature ligand of P-selectin resulted in a significant decrease 
of tracer accumulation in aorta sections from apoE-/- mice, which indicated that the 
accumulation of the radiotracer was especially mediated by cellular P-selectin expression. The 
signal intensities characterized by TBR were significantly decreasing (p < 0.01) from 5.2 ± 0.7 
with no inhibition to 2.6 ± 0.4 with inhibition. Strong decrease at plaque was observed after 
incubation of sLeX on atherosclerotic aorta sections. This blocking effect was obvious on the 
corresponding in vivo (Fig. 17) and ex vivo images (Fig.18) 	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Figure 17:  Representation of Monitoring P-selectin inhibition by sLeX using 68Ga-Fucoidan. A, Sudan 
IV staining of aorta lesion of an ApoE-/- mouse fed with western diet for 40weeks, demonstrating plaque 
development along aorta. B, 68Ga-Fucoidan PET image of aorta lesions from ApoE-/- with severe 
plaque with (left) and without  (right) pre-incubation of overdose sLeX. C, Uptake value at 60 minutes at 
atherosclerotic aorta with and without P-selectin inhibition. Data are given as mean±SD (n=6). *P<0.05. 	  
  
Figure 18: Pre-incubation of sLex target to P-selectin inhibited uptake of 68Ga-Fucoidan in 
atherosclerostic plaques from ApoE-/- mice. A, B, Autoradiography images show the lower uptake in the 
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aorta pre-incubated with P-selectin targeted antibody. Histology demonstrated the co-localization of 
atherosclerotic plaque with the area of increased 68Ga-Fucoidan uptakes by (C) H&E staining and (D) 
DAB staining of P-selectin. 
  
Animal	  Studies:	  Discussion	  -­‐-­‐-­‐	  68Ga-­‐DOTATATE	  Study	  
	   47	  
4.3 DISCUSSION  
 
4.3.1 ANIMAL STUDY I: Macrophage characterization of atherosclerosis:  
68Ga-DOTATATE ex-vivo detection in mice 
Atherosclerosis is a systemic inflammatory disease, knowledge about the macrophage content 
on plaque is especially important to evaluate atherosclerosis. In the present investigation, we 
tested 68Ga-DOTATATE an SSTR-affinity radiotracer in a number of ex and in vitro 
experiments aiming to investigate the tracer’s uptake in atherosclerotic plaques on a tissue 
level, examining, whether this tracer is able to detect atherosclerotic lesions and determine 
macrophage localization. In our previous study, a stronger association of increased 68Ga-
DOTATATE uptakes with risk factors for cardiovascular disease as compared with 18F-FDG in 
oncological patients suggested a potential role of 68Ga-DOTATATE for plaque imaging in the 
large arteries (130). However, until now confirmation of a specific tracer uptake on a tissue 
level was lacking. Therefore, ApoE-/- mice, the most commonly used animal model of 
atherosclerosis were investigated. In this study, we compared the autoradiographic findings 
with histological and immunochemical results. We observed that the areas of high 68Ga-
DOTATATE uptake colocalized with atherosclerotic plaque on excised aortas. Aorta was 
selected but not coronary artery or aortic root, which are more hazardous and prone to 
develop atherosclerosis; since several unspecific myocardial uptakes were also observed, 
which possibly could affect imaging. The significant decrease of 68Ga-DOTATATE uptakes on 
autoradiographic imaging after pre-incubation of the slices with an antibody against SSTR-2, is 
indicative if a high specificity of tracer for SSTR-2 in the vessel wall.  A previous study reported 
that the SSTR-2-mRNAs could be detected in macrophages(114).  In the current study, we 
found significant expression of SSTR-2 on monocyte/macrophages as well by flow cytometry. 
Additional, SSTR-2 were also detected on the T-cells that are nonetheless important in 
regulating immune response and expressed significant at atherosclerotic lesions. In addition, 
LPS-activated and non-activated macrophages were studied to assess the effect of an 
inflammatory stimulus on the expression of SSTR-2. LPS was chosen as a stimulating factor 
because it is a specific activating factor with immunostimulatory effect(131). When 
macrophages were stimulated with LPS, no different expression of SSTR-2 which is in keeping 
with a previous study showing that SSTR-2 mRNA of human macrophage was not up-
regulated by LPS(114).  Conversely, another study demonstrated that significant up-regulation 
of SSTR-2 in LPS-activated human macrophages (113). The cause of this inconformity is 
unclear, a difference in the duration of the stimulation may contribute to this discrepancy. From 
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this point of view, 68Ga-DOTATATE PET imaging is not able to assess the activation of 
macrophage, but just detects their presence. However, It is also commonly known “ vulnerable 
plaques” have a high density of macrophages; detection of those macrophages therefore may 
play an important role in imaging vulnerable plaques. Both a previously published study using 
human coronary endothelial cells and our data on murine endothelial cells demonstrated that 
SSTR-2 is significantly expressed on endothelial cells, however this expression is decreased 
by the treatment with inflammatory cytokine TNF-a, which is mainly produced and secreted by 
activated macrophages.(132) Additionally, in our study significant stronger uptakes at plaque 
area were detected than non-plaque area. We also prove, that 68Ga-DOTATATE may be used 
to assess macrophages within arterial walls. This is the first report directly demonstrating a 
high affinity of 68Ga-DOTATATE to macrophage-rich atherosclerotic plaques.. Therefore, 68Ga-
DOTATATE has the potential to evaluate vascular macrophage density by detecting SSTR-2 in 
humans. However, further investigations are needed to confirm the potential of 68Ga-
DOTATATE-PET as tool for molecular imaging of macrophage clinically. 
 
Limitation 
The in vitro results require animal PET/CT imaging to localize the plaque sites and prove the 
association between in vivo and in vitro study. The 68Ga-DOTATATE PET seems to be an 
efficient modality for detecting vascular inflammation, but the uptake of radiotracer does not 
reflect the morphology accurately. Moreover, though the activation of the inflammation could 
decrease the expression of SSTR-2 on endothelial cells, that can influence accurate 
evaluation of vascular uptake, 68Ga-DOTATATE PET could be recognized as a supplemental 
method for evaluation of vulnerable plaque base on the examination of plaque morphology. In 
our study, all mice were investigated at long-term point, In order to evaluate the sensitivity of 
68Ga-DOTATATE, more investigations of early-stage atherosclerosis imaging are also required 
to be performed. Further correlative studies need to be performed in humans. Also, in this 
study, female ApoE knockout mice were used, which are known to be less affected by 
atherosclerosis than their male littermates. However, also due to the special diet, we observed 
severe atherosclerotic changes also in the female animals in this study.  
Animal	  Studies:	  Discussion	  -­‐-­‐-­‐	  68Ga-­‐Fucoidan	  Study	  
	   49	  
4.3.2 ANIMAL STUDY II: Targeting P-selectin expression in vulnerable 
plaques by Gallium-68 labeled Fucoidan PET: Correlation with in vivo 
17.6T MRI 
In spite of many efforts and great advances in technology, the detection of vulnerable plaque 
at risk of rupture still remains challenging. More sensitive and specific contrast agents are 
required for accurate diagnosis and to guide therapy. Regardless of all imaging modalities, it is 
important to distinguish stable plaques with a low extracellular lipid (types I–III) from vulnerable 
high macrophage-density plaques (types IV and Va), which are dangerous because of their 
high risk of rupture and risk of acute thrombosis (133,134). Increased P-selectin expression 
has been found in vulnerable atherosclerotic plaques; whereas fibrotic stable plaques are 
lacking pronounced P-selectin expression. Thus, noninvasive detection of up-regulation of P-
selectin on activated endothelium could become an effective tool to evaluate the risk of 
atherosclerosis and thrombosis in reducing atherosclerotic lesion development and preventing 
acute cardiovascular events. sLeX-like glycan, which is nature ligand of P-selectin (135) and 
strongly expressed in circulating leukocytes was selected as imaging probe (136). As naturally 
occurring mimic of sLeX, Fucoidan holds great clinical and investigation potential with 
superiority of low cost.  
In this study, we described for the first time to our knowledge a P-selectin affinity PET tracer, 
Gallium-68 labeled Fucoidan, as a promising imaging probe to visualize murine 
atherosclerosis. First, we established an efficient and rapid synthesis of 68Ga-Fucoidan, which 
could be applicable for potential clinical uses. 68Ga-Fucoidan was obtained in an overall 
decay-corrected reaction yield of 90±5% and 99% radiochemical purity in a total synthesis 
time of 40 min. The preparation of 68Ga-Fucoidan was reproducible in providing one stable 
product, as shown by radio-HPLC and radio-TLC analysis up to 4h (equivalent of 3.5 x half-
lifes of 68Ga) after preparation. 
68Ga-Fucoidan was assessed in vitro, ex vivo and in vivo respectively. We found that the 68Ga-
Fucoidan specifically accumulates at unstable plaques with high-density macrophage 
infiltration, but much less at fibrous plaques with low-density macrophage presence assessed 
by autoradiography. In micro-PET study, high specificity and sensitivity were confirmed by 
strongly pronounced uptake at aortic atherosclerotic region with high target to background 
ratio at time point of 50 minutes post injection.  
Numerous imaging technologies such as MRI and SPECT were previously developed to 
detect P-selectin as well. PET as a method is more suitable to detect pathologies on a 
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molecular basis than MRI further more, it has a superior spatial resolution as compared to 
SPECT. In MRI studies, imaging of atherosclerotic endothelium with low-concentrated 
superparamagnetic agents in a low magnetic field was found to be challenging (122). Recently, 
Rouzet et al. reported on a new SPECT tracer, 99mTc-Fucoidan, which was developed to 
detect P-selectin’s upregulation in two different animal models of myocardial ischemia 
reperfusion injury and platelet-rich thrombus (137). In this study, a good targeting efficiency of 
99mTc-Fucoidan was confirmed. Focal uptake of 99mTc-Fucoidan was found in all mice with 
endothelial activation with an uptake ratio of 4.1. Although 99mTc-fucoidan possesses great 
practical advantages because of clinical availability of SPECT scanners, due to the inherent 
limitation of lower spatial resolution of SPECT imaging, especially in the context of imaging 
small structures like atherosclerotic plaques, and another reason of current development of 
PET/MRI scanners and superiority of absolute quantitation, Fucoidan-based PET tracer might 
be able to enhance the clinical implication. Overall, 68Ga-Fucoidan PET imaging holds 
sensitive, specific, economic capability improving its potential to be used as a clinical agent in 
the future.  
In comparison to other potential radiotracers for the identification of plaque vulnerability, 68Ga-
Fucoidan might be superior;  18F-FDG is the most common applied radiotracer in pre-clinical 
studies of atherosclerotic plaques. However, high myocardial and brain uptake of 18F-FDG 
remains a major drawback, if coronaries or brain vessels need to be assessed (130). In our 
previous studies, aorta uptake of 68Ga-DOTATATE, a macrophage affinity radiotracer, likely 
shows greater specificity to the vascular inflammation related to 18F-FDG (127,130). Because 
P-selectin expression is closed associated with increased macrophage infiltration into plaque, 
further correlation between 68Ga-DOTATATE PET,  18F-FDG PET and 68Ga-Fucoidan would be 
of great interest. In addition, Matrix-digesting enzyme (MMPs 2, 3, 9, etc ) in the fibrous cap 
also play vital role in rupture of plaque, MMPs secreted by macrophages , are specific 
indicators of the macrophage activity rather than only macrophage density. Noninvasive 
quantification of MMP activity in atherosclerotic plaques by PET or SPECT has been already 
published in preclinical models (138,139). Massive P-selectin migrates from an inner cell to the 
endothelial surface in response to the inflammatory mediators inducing (140). Therefore, P-
selectin and MMPs PET have specific superiority to detect inflammatory activity of plaques. In 
previous work, PET imaging of other adhesion molecules for atherosclerosis detection were 
investigated. Resembling P-selectin, VCAM-1 expresses in the early progress of 
atherosclerosis, and is favorably localized on endothelial cells overlying on inflamed plaque as 
well. Likewise, Matthias et al (141) developed a new PET tracer 18F-4V for characterization of 
vascular cell adhesion molecule 1 (VCAM-1) on atherosclerotic apoE-/- mice and wild type 
mice with myocardial infarction and heart transplant rejection. In addition, they used PET/MRI 
to investigate signaling pathways of monocytes and their progenitors after therapy of 
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myocardial infraction in atherosclerotic mice with myocardial infraction. RNAi silencing therapy 
of the chemokine receptor CCR2, that is able to inhibit the recruitment of monocyte (56). 
We analysised 10 mice dynamically 50 – 100 minutes post injection of the radiotracer and 
binned the data into time frames of 10 minutes each. The absolute values of tracer uptake as 
expressed by SUV seems to slightly increase over that time period (see new Fig 23, however, 
also the background slightly increased, potentially because of minor P-Selectin expression in 
the muscle. All in all the TBR did not change a lot over time; there was a tendency for a 
decrease after 70 minutes. Visually the delineation of the plaques did not improve of time (see 
Fig. 5). Therefore we selected 60 minutes as the time point for evaluation (also because of 
better count statistics and less noisy images using a tracer with a half-life of only 68 minutes).  
Also in later time points bad count statistics may mimic focal tracer uptake in the vessels. Our 
ApoE-/- model have severe atherosclerosis, with 70% or greater luminal stenosis, and due to 
limitation of PET imaging resolution, It become difficult to accurate localize blood pool in the 
lumen of the vena cava. However, the in vivo PET imaging showed corresponding strong focal 
uptake of advanced plaque lesions. Signals from blood pool adjunct to plaques are also 
positive but lower than plaque signals, due to the promising results of this study the next 
potential study is to move into larger animals like rabbits. Unfortunately, the relatively short 
half-life of 68-Galium doesn’t enable delayed imaging time point for yielding better blood 
clearance, Should the slow blood clearance be noted again, a switch to another radionuclide 
like copper-64 may result in better plaque-to-blood ratios, because imaging at later time points 
would then be feasible.	  
We developed an efficient, rapid and economic synthesis strategy. The fairly easy synthesis 
would make it easy to apply the radiotracer clinically. The pharmacologic effect of fucoidan 
processing anti-inflammation and antithrombotic impact was approved (142,143). In our study, 
toxicity of Fucoidan extracted from algae was assessed. The specificity of 68Ga-Fucoidan was 
confirmed by in vivo micro-PET imaging with low background signal, receptor blocking study 
and biodistribution analysis. The reason we used the SUV in muscle instead of blood pool to 
calculated TBR is because inherent limitation of long blood half-life. However, clear uptake at 
vascular wall was observed at many aortal segments. So far, no reliable method exists to 
reliably detect early inflammatory atherosclerotic lesions (type I, II, III and IV) (144). Within 
early atherosclerosis-prone regions of the vasculature, activated endothelial cells express P-
selectin as well. It is thought to be an effective marker to assess the processes in early 
atherosclerotic endothelial dysfunction (120,145-148) Additionally, expression of P-selectin is 
increased on activated platelets during vascular thrombus formation, which is subsequent for 
growth and stabilization of the thrombus by forming large stable platelet-leukocyte complexes 
(140,148). Since P-selectin plays an important role in cardiovascular inflammation and 
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hemostasis, a validated 68Ga-Fucoidan-PET imaging also holds promising potential in various 
clinical cardiovascular settings, such as thrombosis, myocardial ischemia and evaluation for 
ischemic injury therapies. Consequently, and early detection of the specific up-regulation of 
cardiovascular P-selectin could help to reduce the risk to numerous advanced events. 
However, imaging coronary artery atherosclerosis presents special challenges. These arteries 
are smaller than the PET resolution; in our study, unspecific myocardial accumulation of 68Ga-
Fucoidan is not confirmed, either from cardiac endothelium or coronary artery needs requires 
more symmetric assessments in coming studies.  
 
Limitations 
Due to high inherent sensitivity, PET imaging holds superiority in detection the diseased 
lesions as small as atherosclerotic plaques, but lacking of structural information. Combinations 
with computed tomography (CT) or MRI have a great potential to assess both the activity and 
the anatomic details of diseases. Therefore hybrid scanners such as PET/MRI or PET/CT, 
which should be used for further preclinical and clinical studies. Additionally, to adequately 
reflect the real situation, ApoE-/- mice at young age, which are at early stage of 
atherosclerosis are also significant for the study. 68Ga-Fucoidan in detection of early 
dysfunctional endothelium needs to be investigated. Furthermore, in our study, 68Ga-Fucoidan 
PET show promising capability helping to recognize the activated plaques in ApoE-/- mice 
model. Nevertheless, these plaques are not going to rupture, which can cause thrombosis. 
Long blood half-life of radiotracer is an inherent limitation in plaque imaging. Consequently, 
capability of 68Ga-Fucoidan on detection of more severe cardiovascular events such as 
thrombosis, myocardial ischemia is holding greater promising to assess. 
 
4.4 Conclusion 
In conclusion, we evaluated two PET tracers: 68Ga-DOTATATE and 68Ga-Fucoidan on vascular 
inflammation of atherosclerosis. 68Ga-DOTATATE show specific affinity to infiltrated 
macrophage within the plaques. 68Ga-Fucoidan may hold the potential to discriminate between 
active and inactive atherosclerotic plaques in terms of variant accumulation on different-types 
of plaques.	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5.  PATIENT STUDY 
68Ga-­‐DOTATATE	  PET/CT	  for	  the	  detection	  of	  inflammation	  of	  large	  arteries:	  
correlation	  with	  18F-­‐FDG,	  calcium	  burden	  and	  risk	  factors	  
(This patient study is based on the data analysis from routine oncology patients.)	  
 
5.1 Materials and Methods 
Patients  
A total of 16 patients (12 males and 4 females, age ranges from 48 to 77 years, mean age was 
63.5 years) were retrospectively reviewed by two experienced nuclear medicine physicians. 
The patients were referred to the department of Nuclear Medicine for pre-therapeutic 68Ga-
DOTATATE-PET/CT diagnosis to ascertain the presence of a hypermetabolic neuroendocrine 
tumour prior to radionuclide therapy with 177Lu-DOTATATE. Intraclass correlation coefficients, 
along with 95% confidence for inter- and intra reader were shown in table 4. These patients 
had undergone both 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT for staging or restaging 
within 6 weeks (mean, 3.8 weeks; range, 0.14 to 5.9). None of these patients received steroids 
or had a recent history of inflammation or vasculitis.  
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Table 4. Intraclass correlation coefficients, along with 95% confidence for inter- and 
intra reader. 
 
PET/CT imaging 
All patients underwent 18F-FDG PET/CT and 68Ga-DOTATATE PET/CT on a dedicated PET/CT 
scanner (Siemens Biograph ® mCT 64), consisting of a LSO full-ring PET and a 64-slice spiral 
CT. On the day of 18F-FDG PET imaging, patients fasted for at least 6 h to assure a serum 
glucose level below 130 mg/dL. At the time point of intravenous injection of 4.18±0.88 MBq per 
kg bodyweight, patients received 10 mg of furosemide i.v.. After an uptake period of 80-90 
minutes, transmission data were acquired using a low-dose CT (30 mAs, 120 kV, a 512 × 512 
matrix, a 5-mm slice thickness, an increment of 30 mm/s, a rotation time of 0.5 s, and a pitch 
index of 0.8) extending from the base of the skull or the vertex to the proximal thighs. 
Consecutively, PET emission data were acquired in 3-dimensional mode with a 200 × 200 
matrix with 2 minutes emission time per bed position. After decay and scatter correction, PET 
data were reconstructed iteratively with attenuation correction using dedicated software 
(HD.PET, Siemens Esoft).  
  ICC values using the maximum TBR Measurement (18F/68Ga) 
Parameter 
Left 
carotid 
Right 
carotid 
Aortic 
arch Descending Ascending Abdominal 
Left 
iliac 
Right 
iliac 
Inter-
reader  0.92 0.93 0.97 0.9 0.95 0.94 0.92 0.89 
Agreement 
(18F) 
(0.90, 
0.99) 
(0.83, 
0.98) 
(0.95, 
0.99) 
(0.74, 
0.96) 
(0.94, 
0.97) 
(0.90, 
0.97) 
(0.84, 
0.97) 
(0.87, 
0.93) 
Inter-
reader  0.94 0.96 0.98 0.95 0.96 0.98 0.91 0.91 
Agreement 
(68Ga) 
(0.88, 
0.99) 
(0.91, 
0.99) 
(0.97, 
0.99) 
(0.90, 
0.97) 
(0.93, 
0.98) 
(0.97, 
0.99) 
(0.86, 
0.95) 
(0.80, 
0.97) 
Intra-
reader  0.9 0.82 0.95 0.84 0.89 0.97 0.88 0.82 
Agreement 
(18F) 
(0.70, 
0.97) 
(0.60, 
0.94) 
(0.86, 
0.98) 
(0.66, 
0.95) 
(0.69, 
0.96) 
(0.92, 
0.99) 
(0.67, 
0.96) 
(0.58, 
0.93) 
Intra-
reader  0.81 0.89 0.96 0.97 0.85 0.9 0.87 0.89 
Agreement 
(68Ga) 
(0.51, 
0.91) 
(0.68, 
0.97) 
(0.87, 
0.99) 
(0.91, 
0.99) 
(0.68, 
0.95) 
(0.70, 
0.97) 
(0.63, 
0.96) 
(0.71, 
0.96) 
Data in parentheses are 95% confidence intervals 
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For the assessment of somatostatin receptor expression, a mean dose of 1.29±0.43 MBq 
68Ga-DOTATATE per kg bodyweight was injected intravenously. After a period of 40-60 min, 
CT and PET data acquisition was started using the same parameters as mentioned above. 
 
Image analysis 
All PET/CT scans were reviewed for anatomic localization and amount of focal tracer uptake. 
In each patient, 8 segments of large arteries were analyzed: left carotid artery, right carotid 
artery, ascending thoracic aorta, aortic arch, descending thoracic aorta, abdominal aorta, left 
and right iliac artery.  
Arterial calcifications were also assessed, vascular attenuation of >130 Hounsfield units were 
rated as calcification. The plaque burden was semiquantitatively determined by assessing the 
maximal dimensions and composition of plaque using a scoring system from “0” to “4”(Table 
5). 
Table 5. Calcified plaque scoring system 
Score Calcified occupation of the vessel circumference 
0 0% 
1 ＜10% 
2 10–25% 
3 25–50% 
4 >50% 
The total calcified plaque burden for each of the eight arterial segments was defined as the sum of the 
individual calcified plaque scores 
For PET data analysis, a ROI-based approach was chosen. Maximal “standardized uptake 
values” (SUVmax) for both 18F-FDG and 68Ga-DOTATATE uptake were calculated for all 
segments. Areas in proximity to tumor lesions or organs with a high physiological tracer 
uptake, i.e. the liver, were carefully avoided. At least three fixed-size regions of interest (ROIs) 
were placed to cover the lumen at each site, and the highest value was extracted for the final 
calculation of target-to-background ratios (TBR) Background was defined as the average 
blood-pool uptake as determined by the mean SUV of six different ROIs (diameter of 1 cm) 
within the lumen of the vena cava. The SUVmax was divided by the mean blood-pool SUV in 
order to obtain the TBR (149). We used TBRs of all eight arterial segments for the final 
analysis. To determine whether sites of increased focal uptake of 18F-FDG and 68Ga-
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DOTATATE colocalize, the sites with the highest uptake (within about 30% of the highest 
uptake value) were assessed. Accordingly, arbitrary cut-off TBR values of 3.5 for 68Ga-
DOTATATE and 2.1 for 18F-FDG were chosen, resulting in thirty-seven foci of increased 68Ga-
DOTATATE uptake and thirty-nine foci of increased 18F-FDG uptake. Each of these foci was 
visually assessed for the presence of concordantly increased focal uptake of the other tracer 
and for presence of calcifications in the vessel wall. 
We also assessed the differential vascular uptake of the two tracers in a low-risk group for 
CAD defined as subjects with no more than 1 cardiovascular risk factor (n=8) and a high-risk 
group with at least 2 cardiovascular risk factors (n=8). For ROI assignment, visualization of 
PET/CT images and automated coregistration of the two PET/CT datasets, dedicated software 
(TrueD, Siemens Healthcare) was used.  
 
Statistical methods 
Statistical Package for Social Sciences (SPSS version 11.0; SPSS Inc.) was used for 
statistical analyses. Continuous variables with a normal distribution were recorded as mean ± 
standard deviation (SD). The site-specific blood-pool activities of the two tracers were 
compared using ANOVA. Pearson correlation coefficients were used for the assessment 
association between uptake of the two tracers and presented cardiovascular risk factors: 
plaque burden; hypercholesterolemia; hypertension; smoking; diabetes; family history; history 
of cardiovascular disease; BMI; age and gender. Moreover, intra-class correlation coefficients 
(ICCs) with 95% confidence intervals were calculated to test interobserver and intraobserver 
agreement for TBR. Two-way random ICC values which are greater than 0.8 are accepted as 
a measure of excellent reproducibility. 
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5.2 Results 
 
Patient population 
Relevant baseline characteristics of the patients are reported in Table 6, In brief, 8 out of 16 
patients had a history of neuroendocrine tumors, three suffered from thyroid cancer and the 
remaining 5 patients had different carcinomas. Systemic tumor therapy preceding imaging for 
less than 12 weeks was administered in four patients.  Detailed information on tumor types, 
therapies and cardiovascular risk factors can be found in Table 7. All risk factors were 
recorded in Table 8. 
Table 6. The total calcified plaque burden for each of the eight arterial segments was 
defined as the sum of the individual calcified plaque scores 
Age (yrs) 63.5±8.8 
Gender (M/F) 4/12 
Hypercholesterolemia (%) 31.25 
Hypertension (%) 56.25 
Smoking (%) 25 
Diabetes mellitus (%) 12.5 
Family history of CAD(%) 25 
History of CVD (%) 18.75 
CPB 9.44±8.07 
CVD cardiovascular disease; CPB calcified plaque burden 
CAD: coronary artery disease; CVD: cardiovascular disease; CPB: calcified plaque burden; F: female; 
M: male 
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Table 7. Diseases information of Patients 
Nr. Cancer type Systemic tumor 
therapy within 
the last 3 
months 
Number of 
selected 
positive-uptake 
segements 
TBR_mean 
FDG TATE FDG TATE 
1 renal cell cancer none 8 6 2.9 5.6 
2 follicular thyroid cancer TSH suppressive 
therapy 
7 2 2.6 3.3 
3 pheochromocytoma, 
metabolically active 
(normetanephrines, 
dopamines) 
none 3 4 2.1 3.9 
4 cancer of the gastric-
esophageal junction 
xeloda, single 
dose 2 days prior 
to 18F-FDG -, 6 
days prior to 
DOTATATE-PET 
0 0 1.5 1.8 
5 NET (stomach) none 0 0 1.7 2.2 
6 NET of unknown primary 
(liver metastases) 
none 6 3 2.2 3.4 
7 carcinoid (rectum) one cycle of Lu-
177-DOTATATE 8 
weeks prior to 
18F-FDG -, 9 
weeks to 
DOTATATE-PET 
0 1 1.7 2.9 
8 NET of unknown primary 
(liver metastases) 
none 5 2 2.1 2.9 
9 NET (pancreas) one cycle of 
cisplatin/etoposid
e 1 week after 
18F-FDG; 4 weeks 
prior to 
DOTATATE-PET) 
2 1 1.8 2.4 
10 carcinoid (lung), 
hormonally active 
none 1 2 1.7 2.6 
11 NET of unknown primary 
(liver metastases) 
Sandostatin LAR, 
last injection 4 
weeks prior to 
DOTATATE-PET,  
then stopped 
0 0 1.5 2 
12 NET (ileum) none 2 1 1.7 2.8 
13 NSCLC none 1 8 1.8 5.7 
14 papillary and follicular 
thyroid cancer 
TSH suppressive 
therapy 
2 4 1.9 3.5 
15 follicular thyroid cancer TSH suppressive 
therapy 
2 3 1.9 3.1 
16 uterine cancer none 0 0 1.4 1.3 
NET: neuroendocrine tumor; NSCLC: non-small cell lung cancer; TSH: thyroid-stimulating hormone. 
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Table 8. Risk factors of patients 
Patient 
NO. 
Risk facors (Y/N) 
PB Hyperchol HTN Smoke DM 
Fam 
Hist. 
of 
CVD 
C
V
D 
Age Gender BMI 
1 13 Y Y Y Y N N 73 M 38.06 
2 4 N Y N N N N 63 M 19.82 
3 8 N Y N N N N 66 M 26.59 
4 1 N N Y N N N 48 M 22.15 
5 0 N N N N Y N 56 M 28.6 
6 7 N Y N Y Y Y 77 M 24.86 
7 11 N N N N Y N 58 M 21.16 
8 12 N Y Y N Y N 64 M 24.76 
9 1 N Y N N N N 51 F 20.57 
10 12 Y Y Y Y N N 52 M 28.36 
11 0 N N N N N N 71 F 20.08 
12 25 N Y Y N N Y 61 M 24.22 
13 27 Y Y Y N N Y 74 F 20.06 
14 12 Y Y N N N N 72 M 34.14 
15 5 N Y N Y N N 63 M 26.58 
16 13 Y N N N N N 67 F 16 
PB: plaque burden;  HTN: hypertension; Hyperchol: hypercholesterolemia; CVD: 
cardiovascular disease; 
BMI: body mass index. NS: no significance, DM:	  diabetes mellitus 
 
PET/CT imaging 
When assessing the PET/CT image data we found colocalized uptake of both tracers (Fig. 19) 
as well as foci of increased uptake of only one of the tracers (Fig. 20 + 21). 
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Figure 19: Colocalized focal vascular uptake of 18F-FDG and 68Ga-DOTATATE. Transverse views of a 
61-year-old male patient with hypertension and a history of cardiovascular disease. Positive uptake is 
present on both 68Ga-DOTATATE (upper row) and 18F-FDG PET/CT (lower row) at the same location in 
the abdominal aorta of this patient (red circle). Also, serious calcification was detected at the same 
position. TBRDOTATATE was 6.18, while TRB 18F-FDG was 2.42. 
 
 
Figure 20: Focal vascular uptake of 68Ga-DOTATATE without corresponding focal 18F-FDG uptake. 
Transverse PET/CT images of a 73-year-old male patient with hypertension, hypercholesterolemia, and 
smoking. Intense focal uptake of 68Ga-DOTATATE can be observed in the aortic arch (upper row), 
whereas no focally increased 18F-FDG uptake was seen (lower row). TBRDOTATATE was 7.60, while 
TRB18F-FDG was 1.74. 
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Figure 21: Focal uptake of 18F-FDG but not DOTATATE in the vessel wall. Transverse PET/CT images 
of a 77-year-old male patient. With hypertension, hypercholesterolemia, history of coronary disease and 
a family history of cardiovascular disease. Intense 18F-FDG uptake can be observed in the aortic arch 
(upper row), whereas no focally increased 68Ga-DOTATATE uptake can be seen (lower row). 
TBRDOTATATE was 1.64, while TRB 18F-FDG was 2.50. 
 
On evaluation of the 37 sites with highest 68Ga-DOTATATE TBR value, a colocalized focal 
increase of 18F-FDG uptake was observed in 43.2% (16 sites, 10 sites with calcification, 6 sites 
without calcification) while 56.8% of the sites (21 sites, 6 sites with calcification, 15 sites 
without calcification) were negative. Of 39 sites with highest 18F-FDG uptake, only 28.2% had 
an increased uptake of 68Ga-DOTATATE (11 sites, 4 sites with calcification, 7 sites without 
calcification), while 71.8% of the sites (28 sites, 6 sites with calcification, 22 sites without 
calcification) were recorded as negative (Fig. 22). 
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Figure 22: Colocalization of focal 68Ga-DOTATATE and 18F-FDG uptake. Comparison of 37 foci of 
increased 68Ga-DOTATATE uptake (left) and 39 foci of increased 18F-FDGuptake (right) with respect to 
colocalized focal uptake of the other radiotracer and calcification. Imaging findings were characterized 
as concordant when there was agreement in positive detection with both tracers, and as discordant in 
cases of discrepancy between the two tracers' uptake. 
 
We compared the uptake of the two tracers in between high risk and low risk groups. We 
found the tendency both tracer’s uptake from patients in high risk group is higher than low risk 
group. And the 68Ga-DOTATATE show a statistical significance in more arteries than18F-FDG 
(Fig.23). In the group internal comparison, 68Ga-DOTATATE show higher TBR value in both 
groups, especially in high risk group, more significant high uptake were founded (Fig.24). 
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Figure 23: Comparison between high and low-risk group for cardiovascular disease, in regard to the 
18F-FDG and 68Ga-DOTATATE uptake of big arterial vessels. * Comparison is significant at the 0.05 
level (2-tailed).68Ga-DOTATATE uptake in abdominal, both iliac arteries and mean TBR are significant 
higher in high risk group. Uptake of 18F-FDG only in left iliac artery is higher in high risk group. 
 
Figure 24: Comparison  of 18F-FDG and 68Ga-DOTATATE uptake of big arterial vessels within high and 
low-risk group respectively. ** Comparison is significant at the 0.01 level (2-tailed); * Comparison is 
significant (p < 0.05) level . 68Ga-DOTATATE show higher TBR value in both groups in comparison of 
18F-FDG. In low-risk group, significant higher uptakes of 68Ga-DOTATATE were observed in abdominal 
and left iliac arteries while in high-risk group, more aorta segments such as descending, ascending, 
abdominal, left and right iliac arteries were found that TBR value of 68Ga-DOTATATE PET is significantly 
higher than 18F-FDG PET. 
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In total, 12 patients were examined to have focal increased uptakes of 68Ga-DOTATATE, while 
10 patients were found to have 18F-FDG focal increased uptakes. As previously 
recommended, we also used the mean TBR, which was calculated as the mean value of TBRs 
from eight arterial segments for statistical analyses. Comparison of focal 68Ga-DOTATATE and 
18F-FDG uptake in eight arterial segements were shown in Table 9. 
 
Table 9. Comparison of focal 68Ga-DOTATATE and 18F-FDG uptake in eight arterial 
segements 
Artery Tracer  Mean±SD 95%CI  
for mean 
P value* 
Left carotid 
 
18F-FDG 1.67±0.46 1.42,1.91 ＜0.05   
68Ga-DOTATATE 2.37±1.26 1.70,3.04 
Right 
carotid 
18F-FDG 1.68±0.48 1.43,1.94 ＜0.05   
68Ga-DOTATATE 2.41±1.34 1.69,3.12 
Aortic arch 18F-FDG 1.91±0.33 1.73,2.09 NS   
68Ga-DOTATATE 2.86±1.89 1.86,3.87 
Descending 
aorta 
18F-FDG 1.96±0.39 1.76,2.17 ＜0.01 
68Ga-DOTATATE 3.12±1.38 2.38,3.85 
Ascending 
aorta 
18F-FDG 2.09±0.66 1.74,2.44 ＜0.05   
68Ga-DOTATATE 2.67±0.87 2.20,3.13 
Abdominal 
aorta 
18F-FDG 2.24±0.77 1.83,2.65 ＜0.01 
68Ga-DOTATATE 4.99±2.07 3.89,6.10 
Left iliac 
artery 
18F-FDG 1.62±0.31 1.62,1.95 ＜0.01 
68Ga-DOTATATE 3.13±1.26 2.44,3.82 
Right iliac 
artery 
18F-FDG 1.96±0.47 1.71,2.21 ＜0.01 
68Ga-DOTATATE 3.14±1.35 2.42,3.86 
Mean 18F-FDG 1.91±0.40 1.70,2.13 ＜0.01 
68Ga-DOTATATE 3.08±1.21 2.44,3.73 
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Sub-group analysis 
Two risk-related groups were formed to assess the differential vascular uptake of two tracers. 
The summed calcification scores (CPsum) differed significantly between the two groups 
(p<0.05). TBRmean, TBRabdominal, TBRleft_iliac and TBRright_iliac of 68Ga-DOTATATE of were 
significant higher in the high-risk group (at least two cardiovascular risk factors) as compared 
to the low risk group (at most the one cardiovascular risk factor) (Fig. 23). In contrast, for 18F-
FDG TBRmean and TBRabdominal only showed a tendency for a higher uptake in the high risk 
group; only the TBR value in the left iliac artery was found to be significantly higher (p<0.05).  
Furthermore, in the interval comparison of two tracers within each group, there was no 
significant difference between the two tracers except for the abdominal aorta (p<0.01) and left 
iliac artery (p<0.05) in the low-risk group. However, in the high-risk group, 68Ga-DOTATATE 
showed significantly higher values for TBRmean, TBRdescending, TBRascending, TBRabdominal, 
TBRleft_iliac, and TBRright_iliac compared to the low risk group (Fig. 24) (Table 10) (Table 11) 
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Table 10. Comparison between high and low-risk group for cardiovascular disease, in 
regard to the 18F-FDG and 68Ga-DOTATATE uptake of big arterial vessels and calcified 
plaques 
Parameters     Risk Group     
      
Low Risk (n=8) 
(95% CI for 
mean) 
High Risk (n=8) 
(95% CI for 
mean) 
Sig.  
(p value) 
No. of risk 
factors   0.43 2.88   
Age   59±8.21 (48;71) 67±8.42 (52;77)   
Mean 
(Range) 18F-FDG TBRmean 
1.81±0.40 
(1.48;2.14) 
2.01±0.40 
(1.68;2.35) 0.315 
  
68Ga-
DOTATA
TE TBRmean 
2.47±0.86 
(1.76;3.19) 
3.70±1.24 
(2.66;4.74) 0.038 
  CP sum  
4.75±5.23 
(0.38;9.12) 
14.12±7.86 
(7.55;20.7) 0.014 
TBR 
(Range) 18F-FDG TBRleft carotid 
1.61±0.46 
(1.22;1.99) 
1.73±0.49 
(1.31;2.14) 0.626 
    TBRright carotid 
1.61±0.41 
(1.27;1.96) 
1.76±0.56 
(1.29;2.22) 0.565 
    TBRarch 
1.81±0.34 
(1.52;2.10) 
2.01±0.30 
(1.76;2.27) 0.227 
    TBRdescending 
1.94±0.39 
(1.62;2.27) 
1.98±0.42 
(1.64;2.33) 0.835 
    TBRascending 
2.10±0.89 
(1.36;2.85) 
2.08±0.38 
(1.76;2.40) 0.948 
    TBRabdominal 
1.92±0.45 
(1.54;2.29) 
2.57±0.91 
(1.81;3.32) 0.092 
    TBRleft_iliac 
1.66±0.22 
(1.43;1.81) 
1.95±0.32 
(1.68;2.21) 0.03 
    TBRright_iliac 
1.86±0.39 
(1.53;2.19) 
2.07±0.55 
(1.61;2.52) 0.403 
  
68Ga-
DOTATA
TE TBRleft carotid 
2.02±0.74 
(1.41;2.64) 
2.71±1.60 
(1.37;4.05) 0.29 
    TBRright carotid 
1.84±0.55 
(1.38;2.30) 
2.97±1.67 
(1.57;4.38) 0.089 
    TBRarch 
2.20±0.58 
(1.71;2.68) 
3.53±2.51 
(1.44;5.63) 0.164 
    TBRdescending 
2.60±1.43 
(1.40;3.80) 
3.63±1.19 
(2.63;4.63) 0.139 
    TBRascending 
2.26±0.74 
(1.64;2.87) 
3.07±0.84 
(2.38;3.77) 0.057 
    TBRabdominal 
3.82±1.63 
(2.45;5.18) 
6.17±1.85 
(4.62;7.71) 0.017 
    TBRleft_iliac 
2.49±0.98 
(1.67;3.31) 
3.78±1.29 
(2.70;4.86) 0.041 
    TBRright_iliac 
2.56±1.13 
(1.62;3.50) 
3.71±1.37 
(2.56;4.86) 0.048 
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Table 11. Comparison between 18F-FDG and 68Ga-DOTATATE uptake of big arterial 
vessels within high and low-risk group respectively 
    
18F-FDG  
(95% CI for mean)  
68Ga-DOTATATE 
(95% CI for 
mean) 
Sig. (p 
value) 
Low Risk 
(n=8) TBRmean 
1.81±0.40 
(1.48;2.14) 
2.47±0.86 
(1.76;3.19) 0.067 
  TBRleft carotid 
1.61±0.46 
(1.22;1.99) 
2.02±0.74 
(1.41;2.64) 0.195 
  TBRright carotid 
1.61±0.41 
(1.27;1.96) 
1.84±0.55 
(1.38;2.30) 0.369 
  TBRarch 
1.81±0.34 
(1.52;2.10) 
2.20±0.58 
(1.71;2.68) 0.126 
  TBRdescending 
1.94±0.39 
(1.62;2.27) 
2.60±1.43 
(1.40;3.80) 0.231 
  TBRascending 
2.10±0.89 
(1.36;2.85) 
2.26±0.74 
(1.64;2.87) 0.713 
  TBRabdominal 
1.92±0.45 
(1.54;2.29) 
3.82±1.63 
(2.45;5.18) 0.007 
  TBRleft_iliac 
1.66±0.22 
(1.43;1.81) 
2.49±0.98 
(1.67;3.31) 0.049 
  TBRright_iliac 
1.86±0.39 
(1.53;2.19) 
2.56±1.13 
(1.62;3.50) 0.118 
High Risk 
(n=8) TBRmean 
2.01±0.40 
(1.67;2.88) 
3.70±1.24 
(2.58;5.69) 0.003 
  TBRleft carotid 
1.73±0.49 
(1.31;2.14) 
2.71±1.60 
(1.37;4.05) 0.119 
  TBR right carotid 
1.76±0.56 
(1.29;2.22) 
2.97±1.67 
(1.57;4.38) 0.071 
  TBRarch 
2.01±0.30 
(1.76;2.27) 
3.53±2.51 
(1.44;5.63) 0.111 
  TBRdescending 
1.98±0.42 
(1.64;2.33) 
3.63±1.19 
(2.63;4.63) 0.002 
  TBRascending 
2.08±0.38 
(1.76;2.40) 
3.07±0.84 
(2.38;3.77) 0.008 
  TBRabdominal 
2.57±0.91 
(1.81;3.32) 
6.17±1.85 
(4.62;7.71) 0.001 
  TBRleft_iliac 
1.95±0.32 
(1.68;2.21) 
3.78±1.29 
(2.70;4.86) 0.002 
  TBRright_iliac 
2.07±0.55 
(1.61;2.52) 
3.71±1.37 
(2.56;4.86) 0.007 
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Correlation with risk factors 
Table 12 shows a correlation of 18F-FDG and 68Ga-DOTATATE mean TBR values with clinical 
baseline characteristics. Hypertension significantly correlated with 18F-FDG  (R=0.58, P<0.05) 
and also with 68Ga-DOTATATE uptake (R=0.60, p<0.01). The 68Ga-DOTATATE TBRmean also 
showed a significant correlation with plaque burden (R=0.52, P<0.05); hypertension (R=0.60, 
P<0.05) and age (R=0.56, P<0.05). In addition, plaque burden was also significant correlated 
with smoking (R=0.55, P<0.05) and a history of cardiovascular disease (R=0.63, P<0.01). 
There was a significant correlation between the two tracer’s uptake (R=0.64, P<0.05). 
 
Table 12. Correlation of 18F-FDG TBRmean and 68Ga-DOTATATE TBRmean of eight 
arterial segments to the baseline characteristics  
Pearson's correlation coefficients for the correlation between risk  
factors and imaging results 
 Mean 
18F-
FDG 
Mean 68Ga-
DOTATATE 
PB Hyper 
chol 
HTN Smoker DM Family 
history 
of CAD 
CVD Age Gender BMI 
Mean 
18F-FDG 
1 0.64a NS NS 0.58b NS NS NS NS NS NS NS 
Mean 
68Ga-
DOTATE 
0.64a 1 0.52b NS 0.60b NS NS NS NS 0.56b NS NS 
PB NS 0.52b 1 NS NS 0.55b NS NS 0.63a NS NS NS 
 
aCorrelation is significant at the 0.01 level (two-tailed). bCorrelation is significant at the 0.05 
level (two-tailed). BMI, body mass index; CAD, coronary artery disease ; CVD, cardiovascular 
disease; DM, diabetes mellitus; HTN, hypertension; Hyperchol, hypercholesterolemia; NS, no 
significance; PB, plaque burden  
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5.3 Discussion 
Our study was aimed to investigate the potential of 68Ga-DOTATATE PET/CT to detect 
macrophage density at inflammatory lesions of large arteries. In addition, we compared the 
tracer uptake with that of 18F-FDG regarding colocalization and intensity of the uptake in 
correlation to commonly accepted risk factors for cardiovascular disease. To our knowledge, 
this is the first investigation to compare 18F-FDG and 68Ga-DOTATATE in atherosclerosis 
imaging. 
18F-FDG has already been established as a useful tool to identify inflammatory processes e.g. 
in large arteries (57,79,105,126,149,150). In general, it is taken up by cells in proportion to 
their metabolic activity. Rudd and Tawakol ’s group reported that carotid atherosclerotic 
plaques with high 18F-FDG uptake have a high macrophage density (79,150), indicating that 
18F-FDG might be a useful tool to detect inflammatory plaques. 68Ga-DOTATATE has also 
been demonstrated to detect activated macrophages (115) due to a specific overexpression of 
the somatostatin receptor 2 (SSTR2), the specific molecular target of 68Ga-DOTATATE, on the 
cell surface of activated macrophages.  
Although the potential for macrophage detection has been demonstrated for both 18F-FDG and 
68Ga-DOTATATE, a concordant focally increased uptake was only found in the minority of 
cases in this study. 
When comparing patients with and without risk factors for cardiovascular disease, many sites 
of tracer uptake could be detected both in high-risk and low-risk patients with 18F-FDG. In most 
arterial segments (apart from the ascending aorta), maximum TBR values of the high-risk 
group were higher than those of the low-risk group. However, this difference did not reach 
statistical significance except for the left iliac artery.  
There were few significant differences between the two tracers in the low-risk group. In the 
high-risk group however, TBR for 68Ga-DOTATATE showed significantly higher values than for 
18F-FDG. 
Additionally, significant correlations between the mean uptake of both tracers and the patients´ 
score of risk factors were found. In the literature, several studies reported significant 
correlations between focally increased 18F-FDG uptake in the walls of large arteries and 
presence of cardiovascular risk factors, such as hypercholesterolemia, hypertension, age and 
diabetes (151).  Other study groups found associations between the plaque burden of the left 
anterior descending coronary artery and cardiovascular risk factors (84,149). In our study, only 
a significant correlation between the mean TBR in the abdominal aorta with hypertension was 
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found. The lack of further correlations might be due to the small size of our sample. However, 
we found that age significantly correlates with 18F-FDGuptake in three vessel segments. This 
is in line with previous studies, which demonstrated that the prevalence of visible 18F-FDG 
positive arterial segments increases with age (80,152). For 68Ga-DOTATATE, tracer uptake 
correlated significantly with hypertension, age and the presence of calcifications. 
18F-FDG uptake in inflammatory cells is influenced by macrophage differentiation and cell 
activation (91) since immune cell activation is associated with increased oxidative metabolism 
and consequently, increased use of glucose (105). In our investigation, we found many 18F-
FDG positive sites both in the low- as well as the high-risk group, whereas very few 68Ga-
DOTATATE positive foci could be found in low-risk individuals. This raises doubt whether all 
accumulations of 18F-FDG within the arteries are due to macrophage-mediated inflammatory 
activity.  
In contrast to 18F-FDG, 68Ga-DOTATATE visualizes the distribution of SSTR-2. As mentioned 
above, specific expression of SSTR-2 on the surface of macrophages as well as significant 
upregulation of this receptor upon stimulation (e.g. with lipopolysaccharide [LPS]) have been 
reported (113). Furthermore, another research group observed that the expression of SSTR-2 
in human coronary endothelial cells is decreased by treatment with the inflammatory cytokine 
TNF-α, which is mainly produced and secreted by activated macrophages (132). Therefore, in 
the pro-inflammatory setting, SSTR-2 expression is upregulated for macrophages whereas, on 
the other hand, it is downregulated in endothelial cells. In coronary heart disease, this idea 
could support the use of 68Ga-DOTATATE for the detection of vulnerable plaques. 
SSTR-2 also plays another role in atherosclerotic plaques. Adams et al. demonstrated 
increased expression of SSTR-2 when human umbilical vein endothelial cells (HUVECs) are 
proliferating, thereby suggesting its active role in angiogenesis, which has been described in 
the context of unstable plaques. Consequently, 68Ga-DOTATATE-PET could be used to 
visualize unstable plaques in two different ways; detection of activated macrophages as well 
as angiogenesis within the atherosclerotic lesion (153,154).  Our results indicate that 68Ga-
DOTATATE-PET detects a higher number of increased focal uptakes in patients with high 
cardiovascular risk; this may be used as a complementary imaging modality in the detection of 
inflammatory plaque by identifying somatostatin receptor-positive sites within the arteries.  
In this study risk factors for CAD correlated less strongly with foci of increased 18F-FDG uptake 
as compared to 68Ga-DOTATATE. This might be interpreted as an indication for better 
specificity of 68Ga-DOTATATE for the inflamed plaque. However, due to the small sample size 
of our investigation, it is difficult to draw firm conclusions. For example, another reason for the 
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observed difference between the two tracers could be tracer kinetics. DOTATATE binds to the 
SSTR-2 and, thus, the uptake is potentially is limited by the number of saturated SSTR2 
receptors. This is not the case with 18F-FDG, which is continuously metabolized by activated 
macrophages. Otherwise,  18F-FDG as the smaller molecule is potentially more vulnerable to 
unspecific uptake mechanisms like increased vascular permeability due to inflammation. So, in 
theory,  18F-FDG should be more sensitive than DOTATATE, but potentially less specific, which 
could explain the better correlation with different risk groups. Another important limitation is the 
lack of histological validation of 68Ga-DOTATATE uptake.  
Due to the retrospective design a selection bias cannot be excluded. Also, this study was 
performed in cancer patients; therefore our findings may be not generalizable to studies in 
vascular disease. Especially, we cannot exclude the influence of anticancer therapies or 
hormone action of neuroendocrine tumors. So far, no influence of TSH-suppressive therapy or 
peptide receptor radionuclide therapy (PRRT) on atherosclerosis has been published. In the 
only patient with PRRT the interval to the PET scans was at least 8 weeks, so we do not 
expect any interference. Also, none of the two patients on chemotherapy was immunodeficient 
according to white blood cell count. However, further prospective studies in a higher number of 
non-oncological patients are warranted. In this series of cancer patients, we found a stronger 
association of increased 68Ga-DOTATATE uptakewith known risk factors of cardiovascular 
disease as compared to 18F-FDG, suggesting a potential role for plaqueimaging in large 
arteries. Strikingly, we found that focal uptake of 68Ga-DOTATATE and 18F-FDG does not 
colocalizein a significant number of lesions 
	  
5.4 Conclusion 
In this series of cancer patients, we found a stronger association of increased 68Ga-
DOTATATE uptake with known risk factors of cardiovascular disease as compared to 18F-FDG, 
suggesting a potential role for plaque imaging in large arteries. Strikingly, we found that focal 
uptake of 68Ga-DOTATATE and 18F-FDG does not colocalize in a significant number of lesions	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6. ADDITIONAL STUDY 
Endothelial	  CD81	  is	  a	  biomarker	  of	  early	  atherosclerotic	  plaques	  for	  
molecular	  imaging_Targeted	  superparamagnetic	  iron	  oxide	  (SPIO)	  study	  
 
In our study, we investigate the feasibility for molecular imaging of endothelial CD81 
expression in vitro using the CD81-targeted superparamagnetic iron oxides (SPIO). Cluster 
designation 81 (CD81), a member of the tetraspanin superfamily of cell-surface proteins, tends 
to associate with integrins, with other tetraspanins and with lineage-specific molecules in the 
immune system and participates in diverse biologic activities including cell proliferation (155), 
differentiation(156), adhesion (157) and motility (158,159). Recently, through genetic screens, 
the tetraspanin CD81 was demonstrated to be a marker of early human atherosclerotic 
plaques (160). In their study, CD81 was significantly and specifically upregulated in endothelial 
cells of atherosclerotic plaques and played a crucial role in the initial stages of atherosclerotic 
plaque formation. These data indicate that the expression of CD81 proteins in endothelial cells 
is crucial for genesis and progress of atherosclerosis. In this context, the ability to visualize 
noninvasively the expression of the marker molecule would be very useful both in preclinical 
research and in the clinical setting. Here, we report on the use of antibody-coated SPIO to 
target the CD81 in murine endothelial cells that were treated with the phenazine methosulfate 
(PMS) in vitro.  
  
6.1 Materials and Methods 
Cell culture and in vitro induction of CD81 proteins 
The murine bEnd.3 endothelial cells (1×105 cells/well) were cultured in plates as monolayer in 
Dulbecco’s modified eagles medium (DMEM), supplemented with 10% fetal calf serum and 1% 
penicillin-streptomycin solution (1% v/v penicillin-streptomycin solution containing 5000 units 
penicillin and 5 mg streptomycin per mL) and maintained in a humidified atmosphere 
containing 5% CO2 at 37°C. To induce expression of CD81 proteins, cells were seeded in 6-
well plates overnight to allow cell adhesion. 0, 5, 10 or 20 µL 1 mM of PMS was added into the 
1 mL of media (the final concentration is 0, 5, 10 or 20 µM, respectively) and further incubated 
for 16 h. Cells were collected for Western blot analysis. 
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Western blot analysis for the expression of CD81 proteins 
Stress induced and non-stress induced bEnd.3 cells were lysed in 100 µL ice-cold lysis buffer 
(Radio-immunoprecipitation assay (RIPA). The lysates were centrifuged at 12,000 g at 4°C for 
5 min and the supernatant was collected. 20 µL of supernatant containing the cell total 
proteins was separated by 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) and transferred to polyvinylidene difluouride (PVDF) membranes (Amersham 
Biosciences, Freiburg, Germany). The PVDF membrane was further incubated with 2 mL PBS 
solution containing 4 µL Armenian hamster-anti-mouse CD81 primary antibody (0.5 mg/mL, 
1:500 dilution; BD Biosciences) and was then incubated with 5 mL PBS solution containing 5 
µL goat anti-Armenian hamster IgG HRP-labeled secondary antibody (0.2 mg/mL, 1:1000 
dilution; BD Biosciences). The immunoblot was detected using the enhanced 
chemiluminescence system SuperSignal West Pico Chemiluminescent Substrate (Pierce, IL, 
USA). Quantization of CD81 proteins was carried out using Quanti-One software (BioRad, 
Hercules, CA, USA). 
 
Labeling of targeted SPIO particles 
Targeting moiety was conjugated to the SPIO surface via streptavidin-biotin bridging chemistry. 
Three types of target SPIO were produced.3×1ml Streptavidin-coated SPIO with 20 nm (5mg 
nanomag®-D-spio, Micromod GmbH, Rostock, Germany) was used to combine with 
biotinylated antibody/peptide respectively. CD81-targeted SPIOs (SPIOcd81) were fabricated by 
incubated with biotinylated monoclonal rat anti-mouse-CD81 antibody (100μg, Clone 
YN1/1.7.4, eBioscience). The mixtures were stirred overnight for at room temperature and 
then dialyzed for 48h to remove unbinding antibody (cut-off membrane 300KD). Plain SPIOs 
(SPIOplain) also were used as control. 
 
Animal  
As for the stimulated group, to induce expression of CD81 proteins on vascular endothelium, a 
group of C57 mice (n = 5) were injected by tail vein injection of a dose of 0.25 mg PMS mixed 
in 100 µL saline per 1 kg body weight before killed. As for control group, C57 mice (n = 5) 
were not stimulated by tail vein injection of 100 µL saline. The aorta from all animals were 
obtained for 73russian blue staining and histology. 
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Cell culture and stimulation of PMS 
The murine endothelial cell line b.END.3 was purchased from American type Culture 
Collection. The adherently growing cells were cultivated under standard condition at 37°C in a 
humidified 95% air/ 5% CO2 incubator, maintained in the complete growth medium. It mainly 
including Dulbecco’s Modified Eagle’s Medium (DMEM) (Gibco), supplemented with 10% fetal 
calf serum (Gibco), 100 U/ml penicillin and 100 µg ml−1 streptomycin (Gibco). The bEnd.3 
cells were used at passages 25 to 30. To induce expression of endothelial CD81, endothelial 
cells were seeds into 8-wells cell-culture plates, further 20µM PMS in the media was incubated 
with cells for 16h (71). 
 
In vitro cellular affinity assay 
After inducing of CD81 protein, the binding performance of targeted SPIO was determined. In 
brief, bEnd.3 cells were incubated with SPIOCD81 and SPIOplain at particle concentration of 
107/ml in culture medium for different time interval (10 min, 30 min, 1h and 3h) respectively. 
The whole incubation experiments were conducted with gentle sway. After incubation, the free 
contrast agents within culture medium was removed; and the cells were ready for Prussian 
blue staining after washing thrice with PBS (0.1mol/L. PH 7.4). To evaluate the specificity of 
SPIOCD81, CD81-antibody was pre-incubated with induced cells for 2hs before incubation of 
SPIOCD81. 
 
In vitro vascular affinity assay 
To determine the interaction between SPIOCD81 and the ligand CD81 protein in atherosclerotic 
lesion, ex vivo binding experiments were conducted on the section of murine aortic plaque 
tissue. All of the tissues were obtained from four ApoE-/- mice (30weeks old), and three PMS-
induced C57/6 mice as acute vascular inflammation model.  Were  The endothelial CD81 
protein expression was assessed by Immunohistochemistry method. To evaluate the static 
binding efficiency of SPIOCD81 to the initial and advanced atherosclerotic lesion, SPIOCD81 
(0.1mg/ml) were add to incubate with tissue on the section for 2h respectively at 37 °C. After 
incubation, non-binding USPIO was wash out by PBS. 
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Prussian blue staining 
For Prussian blue staining, bEND.3 endothelial cells and tissue section from ApoE-/- mice 
were washed thrice with PBS and subsequently fixed with methanol and acetone (-20°C). For 
Prussian blue staining, the fixed cells were incubated with 10% potassium ferrocyanide for 5 
min and 10% potassium ferrocyanide in 20% hydrochloric acid for 30 min, and counterstained 
with nuclear fast red. 
 
Immunohistochemistry 
Immediately following final imaging, the carotid artery samples were dissected for histologic 
phenotyping, covered with Tissue-Tek (Sakura, Torrance, CA, USA), and then frozen in liquid 
nitrogen vapor. The carotid artery sections (6 µm thick) were cut with a cryostat microtome 
(CM1950; Leica, Heidelberg, Germany). Double immunostaining was done using 1 µL 
Armenian hamster anti-mouse CD81 antibody (0.5 mg/mL, 1:50 dilution in PBS; BD 
Biosciences) and 1 µL secondary antibody, FITC-labeled rabbit anti-Armenian hamster IgG 
(0.1 mg/mL 1:100 dilution in PBS; BD Biosciences). Cell nuclei were counterstained by 4’,6-
diamidino-2-phenylindole (1:100 dilution in PBS; Invitrogen). Tissue fluorescence sections 
were viewed under a confocal microscope. The mean fluorescent intensity of veins was 
quantitatively evaluated by Image J software (National Institutes of Health, Bethesda, MD, 
USA). 
 
.  
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6.2 Results 
CD81 expression detection 
Rohlena et al. (2009) (160)reported that CD81 proteins can be induced by phenazine 
methosulfate (PMS) and resulted in up-regulation of CD81 expression on the mRNA, as well 
as the protein level. We next examined the dose effect on expression of CD81 proteins in 
response to the oxidative stress inducer PMS. Results showed CD81 was only faintly detected 
in Western blots in non-stress induced bEnd.3 cells. In contrast, incubation of bEnd.3 with 5, 
10 and 20 µM of PMS for 16 h caused a dose-dependent increase in CD81 expression 
(Fig. 25a). Quantization of CD81 proteins is shown in Fig. 25b. There were, respectively, 1.56, 
1.94 and 2.71-fold increases in CD81 expression following the corresponding 5, 10 and 20 µM 
of PMS treatments, compared with those of untreated controls (p < 0.01). 
 
 
Figure 25: Immunoblotting for CD81 expression in bEnd.3 cells. (a) Immunoblotting assay for CD81 
proteins extracted from bEnd.3 cells, which were incubated with 0, 5, 10 and 20 μM of phenazine 
methosulfate (PMS) for 16 h and from untreated control. The top row stands for CD81 proteins, 
indicating a gradual increasing trend with the increase of PMS concentrations. The bottom row stands 
for beta-actins that served here as a loading control and were kept constantly. (b) Quantitative assay of 
CD81 proteins through Quanti-One software. ** p < 0.01 (n = 3). 
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Examination of CD81-targeted SPIO binding affinity to bEnd.3 cells  
To examine binding affinity and specificity, CD81-targeted SPIO and non-targeted SPIO were 
incubated with PMS-stress induced bEnd.3 cells. Results showed there was rarely binding of 
non-targeted SPIO to stress induced bEnd.3 cells. In contrast, a large number of CD81-
targeted SPIO were found to be bound to the surface of stress induced bEnd.3 (Fig. 26) 
 
 
Figure 26: CD81-targeted superparamagnetic iron oxide (SPIO) binding to cultured bEnd.3 cells. 
Representative micrograph for CD81-targeted SPIO or non-targeted SPIO adhered to cells stimulated 
with  10 ithphenazine methosulfate (PMS). Non binding bettwen Non-targeted SPIO and PMS (10 μM) -
induced cells were observed (A). Just a few CD81-targeted SPIO was able to bind to the cells without 
PMS stimulation (B). Greatly Increased uptake of CD81-targeted SPIO were observed at PMS (10 ed 
SPIO werethout PMS stimulation (B). G1 μg/mL free anti-CD81 antibodies with 10 t PMS stimulation (B). 
Greatly Increased uptake of CD81-targeted SPId uptake of CD81-targe 
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In vitro assessment of CD81 targeted SPIO to murine aorta 
In vitro binding affinity of SPIOplain and SPIOCD81 to atherosclerotic aorta, were assessed 
histologically by Prussian blue staining (Fig.27, Fig.28). High-number targeted SPIO 
accumulated at inflammatory aorta wall and atherosclerotic plaque segments, in comparison of 
no binding of non-targeted SPIO were founded at adjacent sections. Corresponding 
immunohistochemistry examinations were performed to confirm increased CD81 expression at 
PMS-induced aorta and advanced atherosclerotic plaque segment (Fig.27C and Fig.28C).  
 
 
Figure 27: Assessment of targeted-CD81 SPIO and non-targeted SPIO in vitro binding to PMS stress 
induced murine endothelium. A. Strong uptake of  targeted-CD81 SPIO at PMS-induced aorta 
segement were observed; B. Non detectable uptake of non-targeted SPIO at induced aorta segement 
were observed. C, Immunofluorescence assay for CD81 expression on the aorta section. 
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Figure 28. Assessment of targeted-CD81 SPIO and non-targeted SPIO in vitro binding to AopE-/- mice 
with advanced plaque. A. Strong uptake of targeted-CD81 SPIO at atherosclerotic segment was 
observed; B. Non detectable uptake of non-targeted SPIO at atherosclerotic segment was observed. C, 
Immunofluorescence assay for CD81 expression on the adjacent section 
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6.3 Discussion 
Given the fact that atherosclerosis is a complex, chronic disorder involving inflammatory and 
proliferative signaling pathways, it is especially important to identify and quantify the specific 
molecular markers of atherosclerosis to provide diagnostic and prognostic information and to 
establish a basis for early atherosclerosis treatment response evaluation.(34,161).  
Numerous molecules unregulated in activated endothelium of vascular disease providing 
potential markers for functional molecular imaging and targeted therapeutics. In previous 
investigation, vascular inflammatory biomarkers have been recognized to reflect essential 
features in the progression of atherosclerosis at early stage. But oxidative stress, another 
important event in formation of atherosclerosis, has less been considered as imaging target to 
evaluate. According to the Rohlena’s finding, the expression pattern of endothelial cell CD81 is 
an ideal molecular marker for evaluating the atherosclerosis prior to the full-blown 
inflammatory response, which triggered us to investigate the feasibility for visualizing 
noninvasively the expression of the marker molecule using targeted MRI contrast agents. 
Phenazine methosulphate (PMS) is a strong oxidant that induces reactive oxygen species 
(ROS) formation in cells. In the vasculature, increased ROS production has been associated 
with endothelial dysfunction, an early pathogenic event in atherosclerosis (162). In our study, it 
has been shown that a dose-dependent manner of CD81 expression after PMS treatment, 
which agrees with Rohlena’s results. 
Western blotting and immunocytochemistry staining are the most popular approaches to 
detect expression of proteins in the preclinical animals or clinic patients. Both need to collect 
ex vivo samples from animals or patients. Usually, invasive surgeries have to be performed 
and a set of experiment procedures has to be followed. In some cases, it is difficult to collect 
samples, particularly for patients with cardiovascular disease.  
High-resolution MRI has emerged as potential promising noninvasive imaging modalities for 
the characterization of atherosclerotic plaques in vivo as it can provide anatomical, structural 
and functional data on the arterial wall. And one crucial challenge for molecular imaging is to 
design a potent contrast agent in sufficient quantity under conditions of shear stress.  
In comparison, although MRI with SPIO still has room to improve, it has some advantages in 
preclinical applications, such as that it is readily available, easy to use and has the fast 
response-time to provide real-time imaging. More importantly, MRI uses contrast agents that 
remain exclusively intravascular, minimizing nonspecific signals from extravasated contrast 
material. Our results indicated that the intensity CD81-targeted SPIO correlates well with 
Additional	  Study:	  Discussion	  -­‐-­‐-­‐CD81-­‐SPIO	  Study	  
	   81	  
relative expression of CD81 by immunoblotting or immunocytochemistry. Although these data 
may not be directly comparable, these findings are especially valuable since imaging can 
provide an alternative strategy for evaluating early response to oxidant stress stimulation in 
terms of spatial extent and amount of endothelial CD81 proteins in a noninvasive or minimal-
invasive manner. In fact, numerous investigators have adopted approaches in which molecular 
imaging has been attained through the use of targeted molecular imaging modalities and many 
proteins related to atherosclerosis such as ICAM-1 (163) VCAM-1 (164) P-selectin (74) von 
Willebrand factor (165) (vWF) and integrins (166), have been imaged. 
In this work, avidin-biotin adhesion was employed between anti-CD81 antibodies and contrast 
agents, given the fact that the strongest known non-covalent interaction between a protein and 
a ligand with an affinity of 1015 M−1 at pH 5. It was found by (167) that by using (strept) avidin 
bridge, both microbubble and SPIO can be easily decorated with a wide variety of ligands or 
combinations of ligands. 
Although targeting with targeted contrast agents for molecular imaging of large arteries is still a 
challenge due to the high shear stress, our results has shown anti-CD81-coated contrast 
agents enables molecular imaging of CD81 expression on vascular endothelium. Our success 
maybe contributes to the relatively small size of SPIO (about 20 nm with centered diameter 
distribution) and high-level expression of CD81 proteins with four transmembrane (TM) helices. 
Indeed, it was demonstrated that a small size favors attachment of targeted contrast agents at 
high shear stresses. With decreasing diameter, the shear stress required to set a particle in 
motion becomes higher (168). Moreover, CD81 is an expressed cell-surface protein, which 
plays in an important role in adhesion (157). The crystal structure of human CD81 large 
cysteine-rich extracellular domain demonstrated each subunit within the homodimeric protein 
displays a mushroom-like structure, composed of five-helices arranged in “stalk” and “head” 
subdomains. These structural characteristics make it more easily form firm adhesion with anti-
CD81 antibodies (169-171). 
Consequently, CD81 also play an important role in cellular adhesive interactions in the 
immune system. And the co-localization of CD81 and inflammation-associated biomarkers 
further confirmed its role in the initial stages of atherosclerotic lesion formation. Here we 
develop a novel CD81 ligand-targeting strategy combined with MR techniques to evaluate the 
oxidative stress within the artery. 
Limitation 
There are several limitations of this study. For MRI molecular imaging, high dose SPIO is 
required to obtain efficient binding in the in vivo study. In addition, it cannot be assumed that 
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the models we used to test the feasibility of CD81-targeted SPIO are identical to disease-
related CD81 expression. In the clinical setting, more complex factors such as disease-related 
inducers, individual differences and intricate signal pathway are often involved into the 
regulation of CD81 expression. Although there is still a long way to translate this technique 
from the animal model to the clinical situation, it is eventually desirable to couple the level of 
video-intensity signal from the targeted molecular imaging to the stage of the disease and to 
the risk assessment of atherosclerosis. Due to there is high patient to patient variation, it will 
be necessary to image besides the effected carotid artery or a control artery, in which the 
expression of CD81 must be less. Furthermore, the accuracy of CD81 quantification using the 
targeted contrast agents may be limited by some degree of nonspecific binding due to the 
wide and overlapping expression of CD81 by the vascular endothelium. Therefore, future 
studies including examination of the feasibility for assessing atherosclerosis and optimization 
of relative parameters using the CD81-targeted SPIO are required. 
 
6.4 Conclusion 
This study has shown that CD81-targeted SPIO may enable expression on vascular 
endothelium in vitro CD81.This oxidative stress associated MRI contrast agent may provide 
reference values of relative expression of CD81. 
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7. CONCLUSION 	  
In conclusion, the 68Ga-DOTATATE studies demonstrated the capability of SSTR-2 targeted 
radiotracer 68Ga-DOTATATE to detect macrophage in atherosclerotic plaque. Accumulation of 
68Ga-DOTATATE co-localized with the atherosclerotic macrophage-rich plaques suggests that 
68Ga-DOTATATE may a suitable tracer for the evaluation of inflammatory activity in unstable 
macrophage rich plaques. And data of pilot patient study demonstrated a stronger association 
between an increased 68Ga-DOTATATE uptake with known risk factors of cardiovascular 
disease as compared to 18F-FDGin a limited number of oncological patients, suggesting a 
potential role of this tracer for plaque imaging in the large arteries and coronaries. Strikingly, 
we found that the focal uptake of 68Ga-DOTATATE and 18F-FDG does not co-localize in a 
significant percentage of lesions. This warrants further investigation on the distribution of the 
two tracers within atherosclerotic plaques 
The P-selectin affinity PET tracer, Gallium-68 labeled Fucoidan, according to this preclinical 
validation study, may hold the potential to discriminate between active and inactive 
atherosclerotic plaques. However, further studies are necessary to elucidate the role of 68Ga-
Fucoidan for atherosclerotic plaque imaging. 
We developed CD81-targeted SPIO to evaluate the oxidative stress in the plaque in terms of 
alternative expression of CD81 proteins stress. Our initial experience using the CD81-targeted 
SPIO has shown that it may enable expression on vascular endothelium in vitro CD81.This 
oxidative stress associated MRI contrast agent may provide reference values of relative 
expression of CD81 and information likely to be very useful to address the detection, 
prognosis, vulnerable potential of atherosclerosis or susceptibility to anti-atherosclerosis 
drugs. 
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9 APPENDIX 
9.1 Abbreviation 
Acute coronary syndrome (ACS) 
Apolipoprotein E (ApoE-/-) 
Bioluminescence imaging (BLI) 
Cardiovascular disease (CVD) 
Cell adhesion molecule (CAM) 
Computed tomography (CT) 
C-reactive protein (CRP) 
DOTA-(Tyr3)-octreotate (DOTATATE) 
Fluorescence imaging (FI) 
Fluorescence reflectance imaging (FRI) 
Fluorescence molecular tomography (FMT) 
Fluorodeoxyglucose (FDG) 
Interleukin (IL) 
Intercellular adhesion molecule 1 (ICAM-1) 
Lipopolysaccharide (LPS) 
Low-density lipoprotein (LDL) 
Magnetic resonance imaging (MRI) 
Molecular imaging (MI) 
Monocyte chemo attractant protein (MCP-1) 
Neuroendocrine tumor (NET) 
Optical imaging (OI) 
Phenazine methosulfate (PMS) 
Positron emission tomography (PET)  
Reactive oxygen species (ROS) 
Single photon emission computed tomography (SPECT) 
Somatostatin receptor (SSTR) 
Scavenger receptor A (SRA) 
Superparamagnetic iron oxide (SPIO) 
Target-to-background ratio (TBR) 
Tumor necrosis factor alpha (TNF-α),  
Ultrasmall superparamagnetic iron oxide (USPIO) 
Vascular cell adhesion molecule 1 (VCAM-1)  
Vascular endothelial growth factor (VEGF) 	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